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INTRODUCTION 
Elderly people, or those over 65 years of age, are known to 
comprise 10% of the United States population today and are projected 
to reach nearly 12% by the year 20001 Further, 5% of this popula-
tion is reported to be institutionalized2 resulting in approximately 
1.1 million chronic care patients or 0.5% of the population. The use 
of drugs in this population comprises approximately 25% of the pre-
scription drug market in the United States3 which is directly related 
to the greater occurrence of pathplogical problems associated with the 
aging process. 1 While it is evident that the beneficial outcome of 
drug therapies is partially related to the increased longevity ob-
served in these elderly people, this population is also well-known 
to be the most prone to adverse drug reactions. 4-6 Factors complic-
ating drug use in the elderly include high usage, chronic therapy, 
long-term hospitalization, inappropriate and multiple prescribing of 
drugs, inadequate monitoring of adverse drug effects, susceptibil ity to 
physical deterioration and senility. 
At the present time, special medical consideration of this segment 
of the population is lacking. Geriatric medicine and pharmacology are 
just beginning to make advances in securing their establishment as a 
distinct and bona fide specialty in health care. Consequently, the 
need for specific studies of drug use and responses in this popula-




Role of the Pharmacist 
The demand for increased pharmaceutical services in skilled nursing 
facilities (SNFs) has been advocated based upon ethical, economic and 
legal reasons . 7-12 A Department of Health, Education and Welfaresurvey, 
completed in 1975, indicated that pharmaceutical services are ''substan-
tially deficient 11 with respect to monitoring drug administration detect-
ing adverse drug reactions as well as prompting optimal drug therapy in 
these facilities. 9 
Recent federal regulations have further delineated requirements in 
the provision of pharmaceutical services to SNFs; " ... The pharmacist re-
views the drug regimen of each patient at least monthly, and reports any 
irregularities to the Medical Director and Administrator. The pharmacist 
submits a written report at least quarterly to the Pharmaceutical Services 
Committee on the status of the facility's ph.armaceutical service and staff 
performance. The pharmacist (not a full-time employee) devote·s a suffi-
cient number of hours, based upon the needs of the facility, during regu-
larly scheduled visits to carry out these responsibilities ..... 13 
In response to these regulations came the addition of special SNF 
14 15 courses in the curriculum of many pharmacy schools across the country, ' 
d 'd. 't. d th 16 ,17 d. fd t'1' proce ure gu1 es 1n mon1 or1ng rug erapy, es1gn o rug u 1 1za-
. 18 19 20 tion rev1ew protocols, ' screening systems for drug interactions 
and schemes for the interpretation of clinical drug data. 21 All of these 
are intended to aid pharmacists in performing these new duties. 
Drug Therapy in the SNF Setti~ 
G . . d h h . h t . t. 5 ' 22 er1atr1c rug t erapy as some un1que c arac er1s 1cs. Responses 
3 
of the elderly to drugs with multiple and chronic diagnoses create a 
•t t • . . . 1 th t • d d "d t• 5~22-28 s1 ·ua 10n requ1nng spec1a erapeu 1c nee s an cons1 era 1on . 
Drug regimens are not often tailored to the geriatric patient. 
While it is well known that the drug-induced illness is much more frequent 
in the elderly,as previously mentioned, they do not generally receive 
dosage reductions of prescribed drugs5 Altered physiology and conse-
quently pharmacokinetic aspects of increasing age include: changes 
in body water and body fat proportions, lowered levels of serum albumin 
and reduced liver and kidney function5,25 , 29 ,30 • In addition, drug-
induced complications may resemble closely the common stereotypes of 
old age : forgetfulness, confusion, tremor, anorexia and anxiety5. 
In the special SNF setting, drug regimens tend to remain rela-
tively the same due to the low frequency of physician contact with the 
SNF patient and therapy is often for chronic disease states. Studies 
conducted in SNFs have shown the average patient to range between 70 
and 80 years old?,Jl and receive 4 to 9 medications8 , 20 ,31 - 33 , further 
indicating that this patient population is a select group. 
Drug Utilization Review (DUR) 
The OUR concept, generically, is intended to describe existing 
patterns in drug use and to identify "problem areas" associated with 
the use of these drugs. One of the first conceptual definitions ap-
peared in the 1968 final report of the Task Force on Prescription Drugs3 
as " ... a dynamic process aimed first at rational prescribing and the 
consequent improvement in the quality of health care, and second at 
minimizing needless expenditure." This definition brings to 1 ight 
that physician drug prescribing is often times "non-ideal" and can 
4 
jeopardize the quality of and add to the expense of health .care. 
There are three basic approaches by vthich OUR can be directed: 
First, a OUR study can be patient-oriented, that is, providing drug 
use data on various patient populations. This approach is advocated 
by Brodie34 and is incorporated into his definition of OUR; 11 ••• the 
on-going study of the frequency of use and cost of drugs, from which 
patterns of prescribing, dispensing and patient use can be determined . 11 
This method is very comprehens·ive in identifying 11 existing11 profiles 
of drug utilization in a given setting, but is based upon drug data 
from dispensing or billing sources rather than the patients• clinical 
record. This OUR approach is generally assisted by an automated 
capability. 
Secondly, OUR can be event-oriented. An event can be interpreted 
as a specific disease state or clinical symptom which is associated 
with the use of a drug(s). This approach is often utilized in adverse 
drug reaction monitoring programs which correlate the occurrence of 
. f. t . th d b . d . . t d 3 5, 36 spec1 1c symp oms w1 a rug e1ng a m1n1s ere . 
Lastly, OUR can be directed toward a specific drug, pharmacological 
class, method of use (i.e., prophylactic antibiotics) or route of ad-
ministration. This method is probably the most common OUR approach 
and is supported by various published guides such as the •Audit of 
Antimicrobial Usage• provided by the Veteran•s Admini stration37 and a 
manual of OUR for the skilled nursing facility38 to name a few. Drug-
oriented OUR is easily adapted to a manual method of data collection. 
Most published studies by pharmacists are of this type and incorporate 
the.ir objective assessment of 11 idea1 11 drug usage. 18 This is based upon 
5 
interpretation · of current scientific literature not usually influenced 
by physician habits or the pharmaceutical indu stry. 
Few st(Jdies have been published which measure the effectiveness of 
OUR studies in improving the quality of drug therapy in SNFs. The pri-
7 mary motivation of these studies was to decrease drug costs or to de-
tl b f . t d . t . 33 crease 1e num er o pat1en me 1ca 1ons But whet her these objectives 
can be associated with improving the quality of drug therapy i s not clear. 
o~ an operational basis, there has been considerable confusion re-
garding the specific objectives and methods of OUR studi~s. St olar39 
recently made a distinction between OUR studies and programs . 
OUR studies involve the measurement or estimate of drug use. They 
may also analyze drug use based on predetermined cri t eria or 11 rational/ 
irrational prescribing ... 
A OUR program, on the other hand, is a method of using OUR studies 
to assure the quality of drug use. Stolar defined a OUR program as : 
11 
•• • an authorized, structured, on-going system for 
improving the quality of drug use within a health 
care organization by evaluating it using predetermined 
standards and initiating efforts to correct patterns 
of drug use which are not consistant with these 
standards. It includes a mechanism for measuring 
the effectiveness of these corrective actions ... 
Therefore, the difference between a OUR study and a OUR program 
is that a program includes the in~tiation of corrective measures and 
a follow-up mechanism to measure effectiveness. 
Determinants of Drug Utilization 
Many factors which influence physician prescribing habits have been 
studied. These factors, for this discussion, will be divided into 
three categories: behavioral, informational and external constraints. 
6 
Behavioral factors include peer group practices, role modeling 
and allied health personnel influences. Many of these influences, 
although not well studied, are known to empirically influence physician 
prescribing. Colman, Katz and Menze1 40 documented that the peer group/ 
colleague interaction was the most influential in prescribing a new 
drug entity. Clinical pharmacist activities in the SNF setting was 
studied by Cheung and Kayne. 41 They showed that if a clinical pharma-
cist was present in a SNF, interacting on a one-to-one basis with physi-
cians and nurses, there was a reduction in the number of · inappropriate 
or unnecessary drugs prescribed. 
Informational influences are the most well known and include drug 
advertising, publications (journal and newsletter) and educational 
inservices. While many of these influences are ubiquitously available 
to the physician, the most successful of these appears to be the drug 
11 detai1 man. ~~ 42 This approach is based upon one-to-one contact with 
repeated reinforcement . Miller43 studied the influence of continuing 
education (drug bulletins and medical staff lectures) but failed to 
clearly show an improvement in drug utilization. 
External constraints relate to administrative policies and proce-
dures, hospital drug formularies or other sources of prescribing edict 
on the state and federal levels. May, Stewart and Cluff44 studied 
prescribing influences in the acute hospital setting and documented a 
profound decrease in propoxphene HCl prescribing when it was removed 
from the hospital formulary. In addition, their study documented a 
change in hypnotic prescribing due to a change in availability from the 
pharmacy. 
Review of Previously Conducted 
OUR Progrdms 
7 
The literature i s lacking in the reporting of a complete OUR 
program as previously defined above. Two OUR programs which are close 
to the definition will be discussed. 
Doeden, et a1. 45 studied gentamicin utilization in the acute care 
setting by retrospective audit. This audit was based ·upon predeter-
mined criteria approved by the Pharmacy and Therapeutics Committee. 
The responsibility for the corrective measures was given _ to the chiefs 
46 of each department in which problem areas occurred. Keys, et al. 
studied warfarin utilization by a similar method to Goeden, et a1. 45 
mentioned above. 
Both these publications utilized retrospective analysis of pre-
determined criteria. This method does not allow f6r the detection of 
"new" or unsuspected problem areas and thereby limits the assessment 
of utilization . Additionally, they do not clearly document the correc-
tive measures implemented nor the results of a follow-up assessment of 
these measures. These two aspects are critical to the determination of 
the effectiveness of the methods of correction and the OUR process 
itself. 
RATIONALE OF THE PROJECT 
The general approach to be used for this project was to involve 
an initial prospective drug-oriented OUR study which would identify 
the problem areas of drug use. This was to be followed by an inter• 
vention period utilizing various educational methods. 
The mechanisms by which these interventions would be implemented 
8 
would include (1) group presentations to the appropriate health pro-
fessionals involved, and (2) inservice education. The behavioral 
factors important would be (1) credibility of presentation as a continu-
ing education and hospital committee function, and (2) use of peer 
advocates from within the institution as support to the presentation(s). 
A follow-up OUR study would then assess the effectiveness of the 
interventions to be used in bringing about the desired change. 
The need for such an approach has been recently stated. Stewart, 
Kabat, and Wertheimer47 emphasize 11 ••• When a UR (utilization review) 
sample study identifies an undesirable deviation from the established 
standards, appropriate educational steps should be undertaken to correct 
the situation follm-,~ed by another study to measure the effectiveness of 
this educational process. 11 Hence, any effort to i;r.prove drug utiliza-
tion must involve a comprehensive and quantitative problem-oriented 
evaluation of all determinants of prescribing, administration and 
dispensing. This should then be followed by an impact analysis of 
the corrective measures implemented. · 
Therefore, the objective of this project is to test the hypothesis 
that the quality and cost of drug therapy in SNF patients can be sig-





Previously published studies indicate that long-term care studies 
are usually conducted in SNFs.J1 ' 33 ,41 ' 47 a This study differs some-
what in that a single large facility was utilized. Laguna Honda Hos-
pital (LHH), owned and operated by the City and County of San Francisco, 
predominantly provides for long-term patients and has a total bed capa-
city of l ,237. This figure includes approximately 5.5% rehabilitation, 
5.5% acute, 3.5% alcoholic treatment, 17.0% women's board and care. 
The remaining beds (843/1237) are for long-term, skilled nursing care. 
Rather than private rooms, these beds are distributed among wards of 
30-55 beds. 
LHH provides its own pharmaceutical services and employs four full-
time pharmacists. The drug delivery system which was in use at the time 
of this study was the traditional ward stock type, utilizing a 'drug 
closet' on each ward. This system involved manufacturer-labeled con-
tainers in each ward 'closet' from which the nurse selected the prescribed 
medications. Future plans were being made, during this project, to 
convert the delivery system to unit dose or patient prescriptions. A 
hospital formulary exists but is not customarily used. In addition, 
aThe term SNF replaced the terms Extended Care Facility and Skilled 




there was no effort to promote prescribing by the Medi-Cal Drug Formu-
lary under which the majority of LHH patients were covered. Since LHH 
is operated by the City and County of San Francisco, the majority 
of the drugs were purchased in conjunction with San Francisco General 
Hospital on a contract agreement \~ith various pharmaceutical manu-
facturers. This enabled these drugs to be purchased at a lower ·cost 
than usual. All .drug billingwas administered by the LHH accounting 
department through a National Cash Register (NCR) computer program. 
This procedure involved non-health related personnel who tabulated the 
drug administrations from weekly patient medication sheets . This 
information was then processed by the computer for the monthly billing 
statements. During this study, LHH was certified for participation 
in both the Medi-Cal and Medicare programs. 
LHH is staffed by approximately twenty physicians including: 
the Medical Director, five full-time physicians and the remainder as 
part-time physicians with private practices in the surrounding com-
munities. Each ward is assigned a primary physician who is responsible 
for routine care. An on-call physician is available in the hospital 
for night and weekend coverage. A profile of the various primary ward 
physicians is listed in Appendix A. A clinical pharmacologist/internist 
served as an advisor to this project (as well as member of the thesis 
corrmittee). 
The nursing staff is composed of approximately 150 licensed 
nurses. This number included the Director of Nursing Services (DNS), 
Assistant Director of Nursing (2), Nursing Supervisors (6), Head Ward 
Nurses (25}, and staff nurses. 
11 
In order to communicate to the physicians and nurses the results 
of this project and to attempt to effect subsequent changes, certain 
meetings were attended. These were the Medical Audit and Utilization 
Review (MAUR) Committee Meeting, the medical staff meetings and the 
head nurse meetings. The i~AUR Committee, which usua lly met monthly, 
was responsible for proposing, conducting, and evaluating medical care 
studies of \'lhich some were drug related. The committee consisted of 
10 physicians (including the clinical pharmacologist), two utiliza-
tion review nurses and the Medical Director. The medical staff meet-
ings were held monthly and attended by the Medical Director and as 
many of the full and part-time physicians as possible. The head ward 
nurses also held monthly meetings which were often attended by the 
nursing supervisors as well. 
LHH has some basic similarities and differences as co~pared to 
the average SNF. The similarities include : (1) nearly all were 
chronic care patients; (2) physician visits were generally monthly; 
(3) 24-hour nursing care was provided; and (4) the hospital partici-
pated in the Medi-Cal and Medicare programs. The differences include: 
(1) its large number of patients; (2) traditional patient wards; (3) 
an in-house pharmaceutical service with a ward stock delivery system, 
and (4) an organized medical staff which met regularly. These charac-
teristics make LHH a rather unique hospital setting for the study of 
long-term care patients. 
Design of the St~ 
A prospective experimental design was utilized for these drug 
studies. A pre-study or control period was conducted for 12 continuous 
13 
Figure 1. Chronology of the OUR Programs. 
X= Psychotropic OUR Study (1974) 
Phase I = Pre-Study Period 
Phase II = Post-Study Period 
Implementation Key: 
Anticonvulsant {AC) 
CD ~J1edica i staff conference 
@ Heoq ward nurse discussion 
@ Physician ·ward rotation · 
Sedative- Hypnotic ( S H) 
Laxative ( LAX) 
® Nursing staff inservice 
@ Medical staf f conference 
@ Head ward nurse discussion 
- @ Physician ward rotation 
® DNS bran memorandum 
@ rv1edical staff conference 
@ Head ward nurse discussion 
@ Physician ward rotation 
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Drug Group SelGction 
Three drug gro11ps were selected for this project: anticonvulsant 
(AC), sedative-hypnotic (SH), and laxative (LAX). The rationale for 
selecting these groups was based upon several factors: 
l) These groups had not been studied by the MAUR Committee. 
2) These drugs were suspected by the medical director, clinical 
pharmacologist and staff pharmacists of being 11mis-utilized 11 • Laxatives 
were overwhelmingly suggested to be a problem drug group in terms of 
both prescribing and administration because of the numerous agents pre-
scribed. This is supported by other investigations indicating that 
catharic and laxative agents are the most frequently prescribed drugs 
in the SNF setting49 ,so· and this was also suspected at LHH. A rela-
tively high rate of SH prescribing was also suspected. This would seem 
to reflect the problem of insomnia commonly believed to be associated 
with geriatric patients50 ,51 . Studies have also been published regard -
52 53 ing the development of tolerence due to chronic use of SH agents ' . 
Much of the prescribing of AC agents in these patients is long-term. 
However, there appeared to be a need to examine this prescribing based 
upon pharmacokinetic principles. In addition, chronic AC ingestion may 
be associated with various drug-induced problems54 . 
3) The drug groups selected for monitoring had relatively 11 large" 
patient populations, enabling a sufficient amount of data to be col-
lected \'lhich would be amenable to meaningful statistical testing. 
4) For the purpose of the intervention aspect of the project, the 
drug groups were also selected such that there were varying degrees of 
physician and nurse influence on prescribingand administration decisions. 
16 
It was anticipated that thi s factor would allow for the eva luation of 
the success of specific educational interventions on physician and/or 
nurse related decision-making. Thus, AC prescribing and admi nistration 
is influenced solely by the physician and is not altered significantly 
by any deci sions made by the nursing staff. SH agents are specifically 
prescribed by the physician, usually as PRN medication and its admin-
istration determined by nurse decision as to need . The selection 
of LAX agents prescribed and their administration is often determined 
by the nurse . This influence i s often exercised via the 11 l axative-of-
choice'' order or in response to pat ient demands for specific LAX agents. 
For this project, the following definitions describe the agents 
included in each drug group: 
1) Anticonvulsant- An agent utilized for management of epilepsy 
or the prevention of seizures. Specific agents in this drug 
group included: phenytoin (Dilantin ®), phenobarbital and 
primidone (Mysoline®). 
2) Sedative-hypnotic- Any agent prescribed only for "h.s." admin-
istration which can induce sleep or cause sedation when given 
at bedtime. Specific agents in this drug group included: 
chloral hydrate, flurazepam (Dalmane ®), diphenhydramine 
(Benadryl ® 1 thioridazine (Mellaril ®), and chlorpromazine 
(Thorazine®). 
3) Laxative - Any agent used to promote the evacuati on and/or 
soften the contents of the bowel. Specific agents and their 
cat~gories included: bulk-forming (Metamuc il ®, Konsy1 ®, 
Patients 
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Effersyll ium ® ), Saline (Mi1k of Magnesia), lubricant (mineral 
oil, Kondremul ®, Agoral ®), stimulant (cascara segrada, 
Senokot ® , and Ex-1 ax® ) , bi sacodyl ( Du 1 co 1 ax® ) , and 
stool-sofeners (dioctyl sodium sulfosucc inate, Surfax ®, 
Doxinate ®). 
Patients selected for the project were those 60 years of age or 
older from 18 (8 female and 10 male) selected long-term , chronic care 
~ards. Two patient selection processes were used for the three OUR 
programs: one for the sedative-hypnot ic and laxative studies and 
another for the anticonvulsant study. 
For the SHand LAX studies, all patients on the 18 wards selected 
were considered eligible. This resulted in 221 females and 260 males 
for a total of 481 eligible patients. From these patients , 130 (65 
female and 65 male) were randomly selected. The same patients were 
used for both SHand LAX studies. It .was assumed that a patient pre-
scribed a LAX agent did not affect the drug action of a SH agent pre-
scribed or vice versa. Phenothiazine agents are not included in this 
assumption because it is known that t hese agents have anti -cholinergic 
acti vity. This affected four patients in the studies. 
For the AC study there were only 59 patients (28 females and 31 
males) receiving AC medication on the 18 wards. Therefore, all of 
these patients v1ere selected and monitored. Eight patients monitored . 
for AC therapy were also among those patients randomly selected for the 
SH and LAX stud ies . It i s possible that a pharmacologi ca l relationship 
between all three drug groups may have occurred (i.e., use of AC agent 
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and subsequent need for a SH) however, the actual extent of this re· 
l ationship cannot be determined and hence was not considered a sig-
nificant bias to the data. 
The same patient population was followed for both the pre- and 
post-studies in each drug group by eliminating data from patients \<Jhich 
had expired during the project. This was done in order to obtain a 
stable and homogeneous population . Consequently, th is population was 
not affected by the discontinuation of AC, SH and/or LAX therapy which 
can occur in critically ill patients prior to death. 
Data 
All data \'/ere collected manually by the author (clinical pharmac ist) 
from individual patient charts on the hospital v1ards. Each ward in the 
project was visited approximately once each 1-2 months for data collec-
tion. Data collection forms were designed specifically for each drug 
group monitored by the author (See Appendix B). They were designed to 
record the following information: 
(l) patient demographic data; age, sex, race, chronic and 
acute diagnoses, 
(2) complete drug regimen, 
(3) clinical laboratory data results, 
(4) detailed information on drug prescribing, administering 
monitoring of possible adverse effects and drug billing. 
These data forms were used for both the pre-study and post-study. 
Following each of these periods, the results were tabulated and sum-
marized manually. 
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IDENTIFICATION OF PROBLEM AREAS 
The pre-study OUR results were used to identify and document prob-
l ems associated with the use of the three drug groups monitored. The 
types of data collected for these studies related to drug prescribing, 
dr ug administration and drug costs. The OUR was examined with regard to 
a number of generalized problems in prescribing or utilization. 
Drug Prescribing 
(1) The knowledge of current pharmacological information by 
the prescriber is often times incomplete. This information, 
or lack of, may potentially include inadequate knowledge of 
drug risk/benefit aspects, drug cost/benefit aspects, and 
newly documented drug information. The problems associated 
with prescriber knowledge have been emphasized in the past 
15 years . Thus, documentation and correlation of adverse 
drug reactions in the early 1960 1 s, 55 Muller•s 1965 pre-
scribing study, 56 the Department of Health, Education and 
Welfare•s Task Force on Prescription Durgs: The Drug 
Prescriber in 1968,57 a~d the National Antibiotic Use Sur-
vey58 on prescriber knowledge have all brought to light 
awareness of this problem. 
(2) The long-term care 3etting is most susceptible to the lack 
of close patient monitoring by the prescdber. Federal 
regulations specify monthly physician visits (special con-
ditions may permit a minimum of one visit every two months) 
for SNFs. Consequently, drug orders are often continued 
without adequate patient evaluation. 13 
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(3) Drug prescribing can potentially be influenced by nurses 
(i.e. LAX agents) without regard to long-term or adverse 
effects of drugs. In most cases, the nurses' knowledge of 
pharmacology, their assessment of drug risk/benefits and 
a\'/areness of the 11 most ideal 11 drug choices may not be 
adequate in order to function as an influence in drug 
prescribing. However, they are the best source of observa-
tion for drug effects, especially in the SNF setting. 
Drug Administration 
(1) PRN orders are administered through nursing decisions 
and serious complications can result from inadequate 
pharmacological information. 
(2) Complex dosing regimens often create excess drug costs and 
extra nursing time required in the admini stration of medica-
tions. Dimascio and Shader59 suggest that the use of single 
daily dosing of psychotropic agents can produce less time 
required to administer drugs. They also s tate that a savings 
in drug costs can occur because large r single doses are 
often less expensive than an equivalent amount in smaller 
doses. This aspect of drug admini stration i s especially 
applicable to the SNF sett ing where nursing staffs are often 
limited . 
(3) Improper adherence to proper dose schedules and regimens 
where time scheduling is pharmacologically important. In-
suffic ient nursing knowledge of proper dosing times and sched-
ules may create problems in drug response and effectiveness . 
Drug Costs 
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Situations such as meal interference of oral antimicrobials, 
decreased absorption of a drug due to a co-administered 
medication, and a missed dose(s) because the patient was not 
in the ward when the medication was passed can all potentially 
affect drug response. Although this is a problem of drug 
administration, it did not particularly apply in this project. 
(1) Drug costs are often not considered by physicians. While 
the goal of drug therapy is better health care rather than 
lower costs, rational and optimal drug prescribing has been 
defined as 11 ••• the right drug for the right patient, at the 
right time, in the right amounts, with due consideration of 
cost.••57 The design of drug formularies often incorporate 
this aspect in their drug selections. 
(2) Drug billing can be inefficient due to drug reimbursement 
restrictions (i.e., medical drug formulary). This situation 
can be associated with a loss of dollars and thus can be 
deemed a problem. 
EDUCATIONAL METHODOLOGY 
The primary approach used in this project to correct identified 
problems in drug utilization was the use of educational interventions. 
The interventions were provided by the author and directed toward 
physiciar.s, nurses and related personnel. The emphasis of the inter-
vent ions depended upon the specific nature of each problem identified 
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and dependent upon the drug knowledge of the health professionals being 
educated. Additional interventions, not directly implemented by this 
project, but which were felt to potentially affect drug prescribing and 
administration,were also accounted for and are discussed below. 
The scheduling of these interventions in this hospital was a slow 
process and involved presentations at meetings and committees which gen-
erally met only once a month. The time required in this project to imple-
ment the various educational interventions for all three drug groups was 
approximately 10 weeks. 
PhysiciDn Directed Interventions 
Interventions were made by the presentation of the OUR results 
to the physicians via combined medical staff - MAUR Committee confer-
d ences. Prior to the conference, a handout was prepared by the clinical 
pharmacist which contained the following information for the physicians: 
(l) Purposes of the OUR study, 
(2) Experimental design, 
(3) Results; patterns of durg usage; drug administration; 
drug cost aspects; and patient outcome, 
(4) Problem areas defined and possible recommendations. 
These handouts with the proposed recommendations "'~re reviewed for con-
tent and credibility by both the medical director and clinical pharma-
cologist prior to the conferences. One presentation was made for each 
d . 
It should be noted that the usual method of presentation of utiliza-
tion studies at LHH was via the I~AUR Committee. The Committee communic-
ated its recommendations to the physician either by a memorandum and/or 
a presentation at a medical staff conference. For these OUR studies, the 
medical director decided that the best method of presentation would be 
directly to the medical staff and consequently the combined conference 
was scheduled. 
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drug group studied. Each OUR was presented by the author, including 
data and possible recommendations. This was followed by an open discus-
sion with support by the clinical pharmacologi st and medical director. 
It is likely that these two physicians may have helped facilitate com-
munications as "peer advocates" to the staff physicians. Physicians 
unable to attend were sent a copy of the OUR handout(s) and reply com-
ments were encouraged. These three OUR conferences comprised the 
primary mode of physician intervention. 
Another physician intervention, totally uncontrolled by the author, 
was a rotation of primary ward physicians which occurred during the 
post-study. This rotation was not routine and was issued as a directive 
by the medical director. This rotation affected 17 of the 18 wards in 
this project. 
Nurse Directed Interventions 
The educational interventions to the nurses were multifaceted and 
dependent upon several factors which helped determine the appropriate 
type and content. These interventions were the mechanism by which the 
nurse related problems were emphasized and communicated. Two important 
considerations were made. 
First, probl em areas associated with individual nurse's behavior 
were determined. Because SH and LAX's were predominantly prescribed 
as PRN orders by the physician, the administration of these drug 
groups were often determined by the indiv·idual nurse as to patient 
need. The educational intervention(s) relating to nurse behavior was 
approached primarily through a general nursing staff inservice education . 
The inse)~vice(s) was presented by the author in a lecture format. (See 
Appendix G for a description of the lecture content). It was felt 
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that the presentation of a OUR study to staff nurses was inappropriate 
and unnecessa1~ due to their limited sci entific background. 
Second ly, problems associated with establi shed nursing policy were 
determined. In contrast to the SHand LAX agents, the AC group is not 
prescribed as PRN orders and were administered through an estab lished 
drug administration policy determined for each ward by the head nurse 
(i .e ., T.I.D. = 9 AM, 1 PM and 5 PM). In general, problems of nursing 
policy were specifically directed through a head \1ard nurse discussion. 
This type of intervention involved a summarized presentation of the 
OUR results by the author followed by an open discussion of the problems 
and recommendations for each OUR study. Physican related problems 
regarding the PRN orders (SH & LAX) were also presented with the inten-
tion of utilizing the influence of the head nurse on the prescribing 
of these drug groups. In addit ion it was emphasized to the head nurses 
that they should correct the problems discussed by either changing 
ward policy or communicating the recommendations to ward personnel 
involved with the problems. 
Other nursing interventions separate from educational or discussion-
type interventions also occurred. Firstly, a memorandum was distributed 
from the DNS to the nursing supervisors and head nurses concerning 
laxative and bran use . This directive was distributed following the 
completion of the nurse related interventions. The memorandum was not 
directly advocated by the author but did reinforce what was emphasized 
in nursing interventions presented. Secondly, contact occurred 
beween the author and both head and staff nurses on the wards. During 
the pre-study period it was known by the head ward nurses and most 
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staff nurses that the author was conducting 11 drug studies. 11 In order 
to e liminate any poss ible effects that this awareness might have, pre-
study results, discuss ions regard ing AC, SH and LAX agents were 
avoided dui"ing this time period. During the post-study this contact 
served as a reinforcement to the nursing interventions provided. Con-
versations often regarded the educational interventions presented and 
the progress of the ward in adopting the proposed recommendations. 
~Jhile thi s type of intervention is difficult to quantify and was not 
uniform in its exposure, it must be considered as a factor in reinforcing 
the nursing interventions provided. 
Pharmacy Directed Interventions 
During the course of this project, drugs vJere distributed by a 
traditional ward stock system. However, a conversion of this system 
to unit dose or patient prescriptions was being planned. Thus , poten-
tial drug di stribution problems with thi s delivery system were more 
ap t to be related to nursing behavior rather than that related to the 
pharmacy. 
~ccounting_Qepartment Directed Interventions 
The accounting department was responsible for drug billing at LHH. 
Prob lems r egarding improper billing of AC, SHand LAX groups, involving 
drug therapy interpretations, were approached through an inservice 
presentation by the author to the individuals involved with the billing 
procedure. The primary emphasis of this intervention was to create an 
awareness of drug administration procedures to these individuals which 
would improve their efficiency of drug administration interpretations. 
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STATISTICAL ANALYSIS 
The purpose of this analysis was to quantify any impact that the 
educational inservices and interventions might have had on prescribing 
habits of the physicians and administration of drugs by the nurses. 
Post-study data were compared to pre-study measurements to assess changes 
in prescribing and administration patterns. A 10 week time period 
occurred between the end of the pre-study and the start of the post-
study. When appropriate, a measurement was mad~ just prior to the start 
of the post-study to account for changes occurring during this time 
period. 
Prescrib.:!.!lg_ 
Two statistical tests were used to evaluate drug prescribing in 
this project. The chi-square test was used for large data values. When 
the data values were too small to permit chi-square analysis, the data 
were evaluated by the Fisher Exact Probability Test. 60 
Several time periods were designated during the post-study according 
to the implementation of the various interventions for each drug group. 
These time periods show the short-term impact of the interventions. Latent 
impact of the initial interventions would be observed in the final time 
periods. Consequently, changes occurring in the final time periods must 
be considered as cumulative of all interventions. 
Prescribing patterns were easily shown from the data regarding the 
frequencies of the various drugs prescribed at a given point in time. 
When these frequencies were measured at various time intervals, changes 
in the drug prescribing were observed. This data showed major increases 
or decreases in the overall prescribing of a given drug. 
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Due to the relatively small number of patients used in this project, 
a more sensitive method of evaluating physician prescribing was used. 
Three prescribing decisions were considered for each drug order: "nev1 
drug order," "discontinued drug order" and "no change in drug order·" (drug 
order renewed) during each designated time interval. 
The evaluation of changes in prescribing decisions involved the· 
entire drug group (chi-square) as well as each agent (or LAX category) 
individually (Fisher Exact). 
The Fisher Exact test required the compilation of the prescribing 
decision data in 2 x 2 format. Consequently, the no-change decisions 
were combined with either the new-order decisions or the discontinued-
order decisions. When the no-change decisions plus the discontinued-
order decisions were compared the new-order decisions, increased 
prescribing 1·1as tested. Vice ve1·sa, the no-change decisions plus the 
new-order decisions compared to the discontinued-order decisions tested 
decreased prescribing for the particular agent. 
Administration 
The changes in the administration of the three drug groups were 
tested by chi-square. 
The administration of the AC agents was determined by the physi-
cians SIG. This l.oJas tested by comparing the frequency of each specific 
SIG during the des ignated time periods. 
The frequency of PRN (Sil and LAX) administration was determined 
from the patients• drug administration record. Each PRN order was 
tabulated according to the number of administrations each week (7 days). 
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The frequency of weekly adntinistrations was divided into four ca te-
gories: 11 not admin istered, 11 11 less regul ar , 11 11 more regu lar 11 and "admin-
i stered daily." 
Drug administrations were measured for 12 weeks in both t he pre- and 
post-study periods. It is important to emphas i ze that this data, based 
on weeklz administration patterns, does not evaluate the continuous · 
administration (or non-administration) for· the 12 weeks of the study 
periqds. 
ANTICONVULSANT RESULTS AND DISCUSSION 
Pre-Study Results 
The results of the initial utilization study, referred to as the 
AC OUR Study, indicate problem areas associated with AC therapy which 
were identified. In terms of implementing changes, these problems 
related primarily to the physicians. 
Distribution 
Fifty-nine (12 . 3%) of the 481 chronic care pati ents received AC 
therapy. Approximately 65% were maintained on one agent, 30% two and 
5% three agents (Table 1) . There was no change in th is distribution 
during the 12 week pre-study period. The predominant pat ient regimens 
(Table 2) were phenytoin alone (58%) and phenytoin pl us phenobarbital 
(PB) (30%). Here again, there were no changes in the reg imens prescribed 
during the pre-study period. 
Ninety-three percent of the AC patients received phenytoin and 
35% PB (Table 3). Primidone was prescribed in 9% of the AC patients. 
Phenytoin, at a dose of 300 mg/day, was prescribed to about 80% of 
the patients while PB was usually prescribed in doses of 45 mg and 90 mg/day 
(Table 4). Sixty-f ·ive percent of the phenytoin orders were prescribed as 
a single daily dose while approximately 35% were prescribed i n divided 
doses, most as t.i .d. (Table 5). Phenobarbital, in contrast, was admin-
istered primarily in divided doses, 80% as t.i.d. and 13% (2/15) as q.i.d. 
Only 7% (1/15) of the PB orders were prescribed as a single daily dose. 
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. Table 1. Percent Distribution of Anticonvulsant(s ) Prescribed per Patient (N=43) . 
Per centage 
Number of Pre-study Post -study 
AC/pt wk 1 wk 12 wk 0 wk ga 
One 65 .1 65.1 67.4 69 .8 
Two 30.2 30.2 27 .9 25.6 
Three 4.7 4.7 4.7 4.7 
Discontinued 0 0 0 0 
aMedica l staff conference on AC drugs and presentation of study data was made on wk 1. 









Table 2. Percent Distribution of the Various Anticonvulsant Therapy Regimens Prescribed 
for 43 Patients. 
Percentage 
Pre-Stud~ Post-Stud~ 
AC R:=gimen wk 1 wk 12 wk 0 wk 9 a 
Phenytoin alone 58.1 58.1 60.5 62.8 
PB alone 2.3 2.3 2.3 2.3 
Primidone alone 4.7 4.7 4.7 4.7 
Phenytoin + PB 27.9 27.9 25.6 23.3 
Phenytoin + Primidone 2. 3 2. 3 2.3 2.3 
Phenytoin + PB + Primidone 2.3 2.3 2.3 2.3 
Phenytoin + PB + Diazepam 2.3 2.3 2.3 2.3 
No AC 0 0 0 0 
aMedica1 staff conference on AC drugs and presentation of study data was made on wk 1. 











Table 3. Percent Distribution of Patients (N=43) Receiving Each Anticonvul sant. 
Percentage 
Pre-Study Post-Study 
AC wk 1 wk 12 wk 0 wk 9a 
Phenytoin 93.0 93.0 93 .0 93 .0 
PB 34.9 34.9 32.6 30.2 
Pr·imidone 9. 3 9. 3 9.3 9.3 
Diazepam 2.3 2.3 2.3 2.3 
Discontinued 0 0 0 0 
aMedical staff conference on AC drugs and presentation of study data was made on wk 1. 










Table 4. Percent Distribution of Total Daily Anticonvulsant Dosage. 
-
Percentage 
Pre-St udy Post-Study 
AC wk 1 wk 12 wk 0 wk 9a wk 13 b 
Phenytoin (N=40 ) 
100 mg 0 2.5 2. 5 2. 5 2. 5 
200 mg 10. 0 10.0 10 . 0 10.0 12.5 
300 mg 82. 5 80.0 80.0 80.0 72.5 
400 mg 7. 5 7.5 7. 5 7. 5 7. 5 
Discontinued 0 0 0 0 5.0 
PB (N=l5) 
30 mg 0 0 0 6. 7 6 .7 
45 mg 46.7 46. 7 33.3 33 .3 33.3 
60 mg 6.7 6.7 6.7 0 6 .7 
90 mg 40 .0 40.0 40.0 33.3 26.6 
120 mg 6.7 6. 7 13.3 13 .3 13 .3 
Di scontinued 0 0 6.7 13.3 13 . 3 
aMedica l staff conference on AC drugs and presentation of study data was made on wk 1. w 
bHead nurse di scussion on AC drugs and a physician ward rotation occurred on wk 1·0. 
w 
., 
Table 5. Percent Distribution of Anti convulsant Frequency of Administration . 
Percentage 
Pre-Stud,l Post-Stud,l 
AC wk 1 wk 12 wk 0 wk 9 a wk 13b 
Phenytoin (N=40 ) 
q.d . 65 .0 65 .0 65.0 70 .0 72.0 
b. i.d. 2. 5 2.5 2.5 2. 5 5. 0 
t. i .d. 27 . 5 27.5 27.5 22.5 12.5 
q. i .d . 5.0 5.0 5. 0 5.0 5. 0 
Disconti nued 0 0 0 0 5. 0 
PB (N=l5) 
q.d. 6.6 6. 6 6.6 26.7 26.7 
b. i.d . 0 0 0 0 6. 6 
t . i .d. 80. 0 80 .0 66.7 53. 4 46.7 
q. i .d. 13 . 3 13.3 20.0 6.6 6. 6 
Discontinued 0 0 6. 6 13 . 3 13 .3 
aMedica1 staff conference on AC drugs and presentation of study data was made on wk 1 . 
bHead nurse discussion on AC drugs and a phys ician ward r otation occur red on wk 10. 
w ..,. 
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There was no change observed in these prescribing frequencies for both 
agents during the pre-study period. 
Dos~~_forms 
Patients receiving both phenytoin and PB can be prescribed either 
a fixed-dose combination (phenytoin lOOmg/PB 15 mg capsule or phenytoin 
lOOmg/PB 30 mg capsule) or the t~JO agents separately. _In the pre-study, 
the fixed-dose combination was administered as frequently as the separate 
dosage forms (Table 6). The use of the fixed-dose combination can be 
considered a nursing convenience due to fewer number of tablets to admin-
ister and less written documention required. Plain PB tablets were 
accounted on controlled drug sign-out sheets. 
Cost 01Jtcome 
There was a cost of 9.0 cents per AC patient-day (Table 7). The 
Medi-Cal billing of these agents was found to be considerablY below that 
which was actually administered. This problem was primarily due to both 
a misinterpretation of single daily doses for phenytoin by the accounting 
department personnel and a master file on drug acquisition prices not 
updated to the current pharmacy drug costs . The accounting department 
error most often related to the single daily administration of phenytoin 
300 mg (three lOOmg capsules) interpreted as lOOmg (one lOOmg capsule) per 
administration . The amount lost showed about 55% of AC drug costs lost 
in this bi lling process. 
Patient Outcome 
The frequency of break-through sei zures reported in the patient 
charts were monitored and found to be very infrequent. During the pre-


















Table 7. Cost Related Outcome of Anticonvulsant Administration. 
Cost of Admin istration for Study Patients (n=43 ) 
Extrapol ation to 
LHH censusa 
Cost ($)b 
Pati ent days/ Cost/pt. day $ Arnt . / year 
12 v;eeks ( $) (1 2 months ) 
Pre Post Pre Post Pre Post Pre Post 
Administered 317.97 319 . 17 3612 3612 .09 .09 3143 .75 3143.75 
Bi 11 edc 145.03 274.36 3612 3612 .04 .08 1397. 22 2794.44 
Lossd .05 . 01 1746.55 349.31 
aMean census= 778; Anticonvulsant usage= 12.3%; Estimated No. of AC pts. = 95 .7 . 
bAcquisition cost to the LHH pharmacy was used for each agent . 
cTabulated from the computerized billing value indicated for each drug order on the patient•s 
Medication Record. 




study period, a total of 3 seizures (reported in 3 patients) were docu-
mented fat the AC patients ·in this study. This corresponds to a frequency 
of 0.28 seizures per patient year and appears to support the absence of 
the stimuli for prescribing changes as observed for these patients during 
the pre-study period. In addition, the break-through seizures that did 
occur were not observed to be related to or subsequently cause a change 
in AC doses or regimens. 
While patients' charts were monitored for changes in patient condi-
tions, a more accurate measurement of AC toxicity (ie. incidence of 
nystagmus, CNS disorientation, lethargy, etc.) would have required addi-
tional patient assessments and would have required much more than the 
study allowed. In addition, AC serum levels were not ordered routinely, 
partially due to the question of the test reliability, and consequently 
could not be utilized as an index of AC toxicity. 
Another aspect of AC patient outcome is the possible development of 
AC induced folate deficiency. It has been reported that the chronic 
administration of AC agents (phenytoin, PD, primidone) may cause a 
deficiency in serum folate levels leading to a possible megaloblastic 
anemia with neuropsychiatric sequelae. 61 -63 Hematology data and serum 
folate determinations were monitored during the pre-study period and 
are shown in Table 8. Serum folate determinations were not made within 
the past year for these patients. Eighty-eight percent of the patients 
showed no record of a serum folate level in their charts. Most patients, 
however, did have mean corpuscular volume (MCV) measurements reported, 
nearly one-half within the past year. Twenty-three percent lacked an 
MCV measurement in their charts. 
I I . I 
Table 8. Screening of AC Induced Fol ate Deficiency (N=43). 
Mean Corpuscular Volume (MCV): 
Pl"'e-Study 
<1 year 44.2% (19) 
>1 year 32.6% ( 14) 
None 23.3% ( l 0) 
Post-Study 55 .8% (24) 
Serum Folate Determination: 
Pre-Study 
<1 year 0% 
>1 year 11.6% (5) 






Frequency of PB Administration 
The frequency of phenytoin administration was primarily once daily, 
however, only 7% (1/15) of the PB orders were prescribed on this dosing 
schedule. The serum half-life for PB is reported to be 77 hours for the 
50-60 year age group and 107 hours for those over 70 years old. 64 Based 
upon this information, once a steady-state serum level is established 
(approximately 2 weeks or 3~ serum half-lives), chronic PB administra-
tion for seizure control can be given once daily. This dosing schedule 
would be expected to decrease nursing time for drug administration as 
well as decrease the possibility of missed dose~ and to reduce drug 
costs. The major objection to this dosing schedule is the possible 
occurrence of excess sedation by the larger dose administered at one time. 
Cost Control 
Fifty-five percent of the administered AC medications were not 
claimed in the computerized drug billing system. This loss, expanded 
hospital-wide, was found to be approximately $1,700 per year. This 
loss was primarily due to a communication problem between the pharmacy 
and accounting department regarding interpretation of drug administrations 
and current changes in pharmacy drug acquisition prices. 
fhenytoin/PB Combination Dosage Form 
The use of the combination dosage form is less than optimal based 
upon the following: 1) the combination dosage form is usually not 
specifically ordered by the physician and therefore can cause confusion 
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to the nursing staff when administered, 2) there is a slightly greater 
drug cost with the combination, and 3) there is less flexibility for 
selecting an individualized patient dosage with the combination dosage 
form. The opposing viewpoint in support for the combination dosage 
form is that less nursing time is needed for its administration. Since 
over one-half (8/14) of the patients on phenytoin and _PB regimens were 
administered the combination form, this was deemed a problem area. 
Screening for Folate Deficiency 
Geriatric patients receiving chronic AC therapy in the SNF setting 
may be labeled as a high risk for the development of folate deficient 
megaloblastic anemia. The specific mechanism for the development of 
this anemia is not known but suspected to be associated with a decrease 
in folic acid absorption from the gastrointestinal tract. 61 On the 
basis of this, a yearly evaluation for the occurrence of this anemia, 
by a serum folate determination, was r'ecommended. 
Interventions 
Physician Intervention~ 
The AC OUR results were presented to a combined medical staff - MAUR 
Committee conference during week 1 of the post-study period (see Figure 1). 
The attendance at the conference included 17 of 22 LHH physicians, includ-
ing the Medical Director and clinical pharmacologist/internist. A handout 
of the AC OUR study was given to the physicians (See Appendix C). The 
data reported in the AC OUR handout is not the same as that reported for 
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the pre-study period. Drop-out patients during the post-study period 
were not included in the final pre-study data. The entire presenta-
tion was about one hour in length and included considerable discussion 
of the problem areas and proposed recommendations. 
The frequency of PB administration was initially questioned with 
regards to the possible oversedation caused by the large daily dosage. 
This was disclaimed by the author on the basis of tolerance to PB seda-
tive effects on chronic administration and that dose scheduling @ H.S. 
could compensate for the possible sedative effects. The clinical pharma-
cologist supported this explanation. In addition, several physicians 
in the audience mentioned that they had prescribed this dosing schedule 
to outpatients with no reported complaints of noticeable sedation. 
The general feeling at the end of this discussion appeared to be in 
acceptance of single daily dosing for PB. 
The presentation of the phenytoin/PB combination dosage form prob-
lem did not, in general, result in much concern from the physicians. 
They supported its use based upon its savings in drug administration 
time to the nurses. 
The yearly screening for folate deficiency by serum folate was . 
met with considerable antagonism by the physicians. This was based 
upon a questioning of the significiance of the deficiency, the use of 
an elevated mean corpuscular volume (MCV) as an initial indicator of 
the anemia, and the extra cost factor of the serum folate determination. 
A totally separate, uncontrolled intervention, the ward physician 
rotation, occurred during week 10 of the post-study period. 
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Nurse Interventions 
The results and problem areas of the AC OUR study \~as discussed 
by the author with the head ward nurses during week 10 of the post-
study period (see Figure l).f Attending the discussion were 14 of 25 
head \'lard nurses. A tape recording was made by the nursing inservice 
director for the nursing supervisors and head ward nurses unable to 
attend the discussion. The entire discussion was about one hour long. 
See Appendix F for an outline of the discussion. 
In general, the discussion of the AC problem areas appeared to be 
met with very good acceptance from the nurses. The possible confusion 
caused by the administration of the phenytoin/PB combination dosage 
form was discussed and a favorable response was voiced to clarify these 
orders. 
Cost Control Interventions 
The procedure for the billing of drugs involved the interpreta-
tion of drug administrations by accounting department personnel. These 
individuals had not received any appreciable health related training. 
An inservice was given to these individuals (2) during week 2 of the 
post-study period. This inservice specifically involved the problem 
of single-daily dose interpretations for AC agents, but other drugs 
were also discussed. 
Post-Study Results 
The success of the interventions was measured immediately following 
their implementation and was shown as the two time periods (week 1-8, 
fThe SH and LAX OURs were also presented at this discussion. 
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week 9-13) of the post-study. It is obvious that each of the time 
periods are not independent of each other and that there was possible 
can~yover influences in the second period from the first. Neverthe 1 ess, 
these time periods do attempt to detect the short-term impact of each 
intervention(s). In some cases, changes appeared to be linked to a 
specific intervention, although other changes are probably due to the 
effects of multiple interventions. 
Demographic Data 
Forty-three patients (20 female and 23 male) remained at the com-
pletion of post-study period. Dropout patients included 12 expired {6 
female and 6 male) and 4 transfers (2 female and 2 male) from LHH . 
The demographic characteristics of the population are summarized 
in Tabl es 9 and 10. The mean age was 69.7 years and nearly one-quarter 
(23%) were black. There was an average of 2.7 chronic diagnoses per 
patient. 
Distribution 
The major impact of the implementation program regarding AC prescrib-
ing concerned the frequency of chronic AC administration. The trend of 
less frequent, single daily dosing of phenytoin is shown (Figures 2 and 
3). This increase initially occurred following the medical staff con-
ference but was not statistically significant using the chi-square test. 
There was also less frequent dosing of PB following the medical staff 
conference (Figures 4 and 5). This change was very significant (P< 0.01) 
when the data was t es ted by chi-square distribution as 11 more frequent" 
(t.i.d. + q.i.d.) and 11 less frequent 11 (b.i.d. + q.d . +discontinued) 
over both pre- and post-study time periods (Table 11). 
I 
Table 9. Anticonvulsant Demograp hic Data: Patient Characteristics. 
Total patient population (N) = 43. 
Age (years) Race 
mean 69.7 caucasian 72.1 % 
range 60 - 95 black 23 .3% 
other 4.7% 
Sex 




Table 10. Anti convulsant Demographic Data: Chronic Diagnoses 
Mean number of diagnoses/pt . 2.65 




Chronic brain syndrome 
Arterioscleroti c heart di sease 
& hypertension 
Skclatal/muscular disorders 
Chronic obstructive pulmonary disease 
Diabetes melli tus 
Congestive heart fai lure 
Senile psychosis 
Cancer (various) 


















Figure 2. Dosage Schedule of Phenytoin Administration Durinq Pre- and Post-Studies. 
A = Medical Staff Conference on week 1; 
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Figure 3. Frequency of Phenytoin Administration During Pre- and Post-Studies. 
A = Medical Staff Conference on week 1; 
B = Head Ward Nurse discussion and Physician rotation on week 10. 
a T.I.D. plus Q.I.D. 
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Figure 4. Dosage Schedu1 e of Phenobarbital Admi ni strati on During Pre- and Post-Studies. 
A; Medical Staff Conference on week 1; 
B ; Head \~ard Nurse discussion and Physician rotation on week 10. 
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Figure 5. Frequency of Phenobarbital Administration During Pre- and Post-Studies. 
A = Nedical Staff Conference on week 1; 
B = Head Hard Nurse di.scussion and Physician rotation on week 10. 
aT.I.D. plus Q.I.D. 
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Table 11. Frequency of Phenobarbital Administration (N=15) 
Pre-Study 
Frequency wk 1 
More Fequent a 14 
L:=ss Frequentb 1 
Chi-Square 2 = 12 .63/4 df p < 0 . 01 X 
a Q.I.D. plus T. I.D. 

















Very little change occurred in the prescribing of AC agents fol-
lowing the interventions in the post-study, as shown in Table~ 2 and 3. 
This was expected because it was not emphasized to the physicians to 
change AC regimens or dosages. It was observed, however, that one 
patient was taken off AC therapy entirely (phenytoin 100 mg t.i.d.) fol-
lowing the physician ward rotation. This discontinuation was not related 
to the development of an adverse reaction to phenytoin but rather to the 
observation made by the new ward physician that the patient had not ex-
perienced any se i zures within the past 3 years. This patient was moni-
tored for 6 weeks following the discontinuation with no reports of 
seizures in the patient's chart. 
Dosage Forms 
The recommendation to decrease the administration of the fixed-dosa 
phenytoin/PB combinat ion (Table 6) 1'/aS not \<Jell accepted by both the 
..... 
physicians and nurses. Consequently, the prescribing of the fixed-
dose combination \'las relatively unchanged during the post-study period. 
Cost Outcome 
A dramatic decrease in the estimated loss of AC costs occurred in 
the post- study period as shown in Table 7. The almost 55% loss indicated 
in the pre-study was reduced to a more acceptab le 11 %. Thi s change 
appears linked to the inservice provided to the account i ng department 
and to the update of the computer Master Code File on drug prices. The 
update was initi ated by the pharmacy and occurred prior to l'teek 0 of 
the post-study . This could be related to the discuss ions bet~>Jeen 




Consistent with the negative response of the medical staff, no 
folate determinations were noted in the charts of the patients monitored 
during the post-study period (Table 8). However, current MCV values 
were available on many of the patients. 
A total of 10 break-through seizures occurred in four patients 
during the post-study period. In general, no noticeable change occurred 
between the pre- and post-studies regarding break-through seizures. The 
seizures that did occur tended to be associated with the same patients 
during both studies. 
DISCUSSION 
The prevalence of AC usage in this elderly patient population at 
I 
LHH was 12.3%. This compares to 5% reported in the acute care setting. 65 
This usage in elderly patients was not related primarily to the diagnosis 
of 11 true 11 epilepsy but due to other chronic diagnoses accompanied by a 
seizure disorder, notably alcoholism and CVAs. The demographic data 
for the AC patients (Tables 9 and 10) showed that 49% had a diagnosis 
of a CVA and 42% a history of chronic alcoholism. As a comparison, a 
randomly selected patient group (same age group and wards) at LHH revealed 
only 29% had CVAs and 21% chronic alcoholism. In addition, the patients 
receiving ACs had a lower mean age (69.7 years to 76.9) t han the randomly 
selected patients. The demographic data also showed that only 49% of the 
AC patients had formal mention of a seizure disorder in their charts. 
This raises question to actual occurrence and severity of the past history 
of a seizure disorder. 
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Indeed, the treatment of seizure disorder in the elderly tends to 
be very ci1ronic with automatic continuation of the drugs . This chronic 
. . 
use without re-evaluation of need raises the question of what toxicities 
can be associated with 5, 10 or more years of AC exposure . Chronic AC 
therapy is knmm to produce hemato 1 ogi c reactions, peri ph era 1 neuropathy, 
vitamin 0 deficiency, and osteomalacia or rickets. 65 The answer to this 
question is not entirely known and there is certainly a need fo r great~r 
study of this aspect of geriatric pharmacology. 
In this long-term care setting, AC prescribing appeared to be 
without change and generally adhered to chronic maintenance therapy. 
Thi s is supported by absence of dosage or agent prescribing changes 
during the 12 weeks of the pre-study period. In addition, most patients 
in this study should be considered as having "contro1l ed 11 seizure dis-
orders due to the relatively low frequency of reported seizures (0.28 
seizures per year) during the pre--study period. Consequent ly, AC~ 1·egimen 
will generally continue unti"l either seizures occur, AC toxicity is 
observed or the patient refuses to take the medication. 
Following the physician rotation (weeks 10-13) one patient was 
abruptly discontinued from phenytoin therapy. The patient '.>tas followed 
for s ix weeks after the discontinuation for the occurrence of seizures 
'.>Jhich did not occur . In li ght of this case, as an exception, the 
chronicity of the majority of AC regimens seems to be unquestioned. 
Because cf the possible sporadic occurrence of seizures, physicians may 
be re 1 uctant to ans'.>ter the questions ·of whether these agents are still 
necessary or \>that is the m·inimum effective dosage for control of patient 
se·izures. 
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Feldman and Pippengee66 studied serum phenytoin levels and found 
seizure-free epileptic patients with AC blood levels below the accepted 
therapeutic level. They attributed this to the occurrence of 11 epilepsy 
in remission. 11 This might also apply to elderly patients on AC regimens 
related to a history of CVAs or alcoholism 1t1ho have been seizure free 
for a long period of time. A further aspect is the time factor for 
discontinuing the regimen versus continuing. The abru pt discontinuation 
of AC regimen can be potentially hazardous and consequently a gradual 
reduction of dosage over several weeks to months is usually practiced. 
This practice may be time consuming in terms of monitoring the patient 
for seizures andevaluating the AC dosage(s). In light of this, H may 
be much easier for the physician to continue the regimen than t o adjust 
the dosage to a minimum in this setting. 
Another prescribing problem, revealed from the AC OUR study, 
relates to the potential problem of inappropriate AC use. The relatively 
high frequency of use in patients with a chronic alcoholism diagnosis 
could presumably be r~lated to withdrawal symptoms rather than a defined 
seizure disorder. This problem, unfortunately, was not presented at 
the medical staff conference because chronic diagnosis indications for 
AC therapy w2re not considered at that time . 
A final pi'2scr·ibing problem of chron ·ic dos ·ing of AC agents ~tms 
specifically addressed by the AC OUR study and presented in t he medical 
staff conference. PB prescribing, in the post-study period, showed a 
significant change (P < 0 .01) toward less frequent dosing and an increase 
from 7% to 27% of the PB patients on single daily dos ing as advocated 
in the medical staff conference. These results are quite dramatic con-
sidering the established prescribing regimens descri bed in the pre-study 
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period. It is proposed that the content of the presentation and the 
open . discussion with the physicians at the medical staff conference was 
a major factor in the success of this intervention . Further support 
of the outcome of this prescribing change was the absence of noticeable 
break-through seizures occurring in the post-study period. 
There was a question of whether a large single dose of PB would 
result in oversedation. During the discussion of this matter, one physi-
cian asked the other physicians if any had prescribed PB in this manner 
and if the patients noted any sedative effects. Several responded in 
support of the single daily dosing without noticeable sedation . This 
latter aspect of the presentation at the medical staff conference, a form 
of spontaneous peer conferment, was an unexpected source of credibility 
in support for the prescribing recommendation. 
This intervention directed toward improving drug prescribing worked 
well at LHH with its organized medical staff. This situation is not 
often the case for most SNFs and other specific methods of physician 
intervention need to be investigated for these settings. However, the 
basic framework of the OUR as the tool or medium in achieving improved 
drug prescribing is clearly documented here. 
The OUR study additionally documented an error in the drug billing 
process. Appropriate educational interventions were implemented which 
resulted in a large dollar savings of unclaimed AC costs. While the 
author was not specifically trained in pharmacy administration or drug 
billing concepts, he was able to incorporate a rather simple method of 
asses si ng drug cost expenditures along with the clinical OUR data. This 
aspect of OUR, even though non-clinically rel·ated, is important to the 
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overall assessment of utilization and should be considered a necessary 
parameter for such studies. • 
In summary, the major impact of the medical staff presentation 
related to a significant increase in single daily dosing of PB. The 
presentation of the prescr ibing data, discussion of the pharmacokinetic 
principles of PB dosing and the spontaneous peer-conferment among phy-
sicians at the presentat ion appeared to be important in causing this 
prescribing change. 
In contrast, the suggestion for routine screening for AC induced 
folate deficiency was not well ackno~1ledged by the physicians. The 
presentation of this problem area lacked supportive clinical data. 
The cost aspect of the AC OUR study discovered an error in AC 
billing . This problem was corrected in the post-study following an 
inservice to the accounting department personnel. It is important to 
include this aspect of OUR to insure efficient cost control of dr~g 
administration. 
SEDATIVE-HYPNOTIC RESULTS AND DISCUSSION 
Pre-Study Results 
The results of the initial utilization study, referred to as the 
SH OUR study, indicate problem areas associated with SH therapy which 
were identified. In terms of implementing changes, this portion of 
the study related to both the physicians and nursing staff. 
Distribution 
Seventy-seven percent (67/87) of the patients studied were pre-
scribed a SH agent (Table 12) in week 1 of the pre-study period. This 
percentage fluctuated very little over the 12 weeks of the pre-study. 
The majcrity (73%) of the patients were prescribed one agent, and 5.0% 
were prescribed two SH agents (Table 13). The latter group usually 
received a phenothiazine (administered only at bedtime) along with a 
more traditional SH agent. Little change in prescribing was observed 
for the 12 \veeks of the pre-study period. Chloral hydrate was the most 
frequently prescribed SH (45%) in the patient population (Tables 14, 15). 
Flurazepam and diphenhydramine were prescribed to a l esser degree, 
14% and 15% respectively. The prescribing frequencies for these agents 
showed virtually no change in the pre-study period. The prescribed . 
dosages9 of the agents were 500mg for chloral hydrate, approximately 
9oata not presented in tables. 
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wk 1 wk 12 wk 0 wk sa 
77.0 78 .2 74.7 72 . 4 
wk 135 
69 . 0 
aMedical staff conference on SH drugs and presentation of study data 
was made on wk 1. 
bHead nurse discussion on SH drugs and a physician ward rotation oc~ 
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Table 13. Percent Di stribution of Sedative-Hypnotic Prescribed per 
Patient (N=87) 
Percentage 
Num ber of Pre-Stud~ 
SH/pt. wk 1 wk 12 wk 0 
None 23 .0 21.8 25.3 
One 72.4 73.6 71.3 
Two 4.6 4.6 3.5 
Post-Stud~ 




aMedical staff conference on SH drugs and presentation of study data was made on wk 1. 
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Table 14. Percent Distribution of the Various Sedative-Hypnotic Regimens 
Prescribed in 87 Patients. 
Percentage 
Pre-Study 
SH Regimen wk 1 wk 12 wk 0 
Chloral hydrate 43.7 44.8 42.5 
Flurazepam 13.8 13.8 13.8 
Diphenhydramine 12.6 12 .6 11.5 
Diazepam 1.1 1.1 1.1 
Thioridazine 1.1 1.1 2.3 
~1u 1t i p 1 e SHe 4.6 4.6 3. 5 









27 . 6 
aMedical staff conference on SH drugs and presentation of study data was made on wk 1. 
bHead nurse discussion SH drugs and a physician ward rotation occurred on wk 6. 
cRegimens of chloral hydrate plus phenothi azine, flurazepam plus phenothiazine, and 











Table 15. Percent Distribution of Patients (N=87) Prescribed Each Sedative-Hypnotic. 
Percentage 
Pre-Study Post-Study 
SH \'Jk 1 wk 12 wk 0 wk sa 
Chloral hydrate 47.1 48.3 44 .8 43 .7 
Diphenhydramine 14.9 14.9 13.8 12.6 
Flurazepam 13.8 13.8 13.8 12 .6 
Diazepam 1.1 1.1 1.1 2.3 
Thioridazine 3.5 3.5 4.6 4.6 
Chlorpromazine 1.1 1.1 0 0 
aMedica1 staff conference on SH drugs and presentation of study data was made on wk 1. 











equal prescribing of 15 mg and 30 mg flurazepam, and 50 mg for nearly 
all diphenhydramine orders. 
0 
PRN Prescribing 
The majority of SH agents were prescribed H.S. PRN . Only 8 of 72 
SH orders were prescribed Q.H.S. 
PRN Administration 
The fre~uency of PRN administration data are graphed in Figures 6 
to 9. The values were reported as the average (with standard deviations) 
for the 12 ~tteeks of the pre- and post-study periods. The 11 total" cate-
gory is the \'/eek"iy sum of all four administration categories. 
Approximately 725~ of the SH orders were 11 not administered 11 each 
~tteek while 18% were 11 admini stered daily 11 (Figure 6). 11 Less regular 11 and 
11 more regular 11 administration occurred less, 4% and 2% respP.ct ive·ly . 
These findings of either daily administration and non-administrat~on for 
SH agents in the SNF setting have a 1 so been documented by Ma rtt il a, et 
a1.51 and Ingman , SR, et a1. 89 Figures 7, 8 and 9 shm.; the frequency of 
administration for chloral hydrate, flurazepam and diphenhydramine 
respectively. All three agents showed similar administrat ion patterns 
as to that previously described above. Chloral hydrate, however, resulted 
in over 90% of the orders 11 adrni n i stered daily. 11 
Non-specific Prescribing 
Three of the 11 diphenhydramine ordered administered at bedtime 
were written as PRN without a specifi ed indication (Table 16). However, 
the nursing doeuffi'.!'t:.trt ti'tmf Ci!f .t he:: re ;J..~qn: :for PRN administration indicated 
that they were given for sleep. 
68 
0 
Figure 6. PRN Administration for All SH Agents During Pre- and Post-Studies. 
Pre-Study = wk 1 - 12; 
Post-Study= wk 2 -13; 
Vertical bars = +l Standard Deviation 
aAdministered 1 - 3 times per week. 
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Figure 7. PRN Administration for Chloral Hydrate During Pre- and Post-Studies. 
Pre-Study= wk 1 - 12; 
Post-Study = wk 2 - 13; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 
bAdministered 4 - 6 times per week. 
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Figure 8. PRN Admin1stration for Flurazepam During Pre- and Post-Studies. 
Pre-Study= wk 1 - 12; 
Post-Study = wk 2 - 13; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 
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Figure 9. PRN Administration for Diphenhydramine During Pre- and Post-Studies. 
Pre-Study= wk 1 - 12; 
Post-Study= wk 2 -13; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 
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Table 16. Diphenhydramine PRN Orders Administered Only at Bedtime. 
Percentage 
Physician Pre-St:.Jd~ Post-Stud~ 
Order wk 12 wk 0 wk 12 
SpecHieda 8/13 ( 62. 0%) 1 0/12 ( 83 . 0%) 6/9 ( 67 .0%) 
Not Specified 3/13 (23.0%) 0/12 1/9 (11. 0%) 
IIQ.H.S.IIb 2/13 (15 . 0%) 2/12 (1 7 . 0 ~~ ) 2/9 (22 .0%) 
aindicated for insomnia or sleep. 





The overall expense for SH administration during the pre-study 
period was relatively low, due to the fact that most orders were not 
administered (Table 17). However, the amount for those billed was less 
than the administered value. This was primarily related to the admin-
istration of flurazepam. Flurazepam was the only SH agent not reim-
bursed by the Medi-Cal formulary and consequently its admi nistration 
cost was absorbed by LHH. Measures to provide reimbursement for flura-
zepam administration were not taken. This loss, expanded hospital-
wide, was estimated to be $369.19 per year or approximately 30% of the 
SH costs. 
Patient Outcome 
El even repea t doses were administered to five pati ents during the 
pre-study period (Table 18). This can be compared to either the total 
number of SH doses administered during the period, (ll/1763) or to 
number of patients prescribed SH agents (5/68). Both comparisons result 
in a low occurrence of repeat doses required. However, it was noted 
that most pati ents requiring repeat doses had been receiving daily 
adm inistrations whi ch tends to support the fact of the development of 
tolerance to routine SH use and consequently the requirement of l arger 
doses. 
Problems Identified 
Routine Adm ini strat ion of SH Agents 
Routine, daily administration of all SH agents can be assoc iated 
with poss ible development of tolerance and hence a decrease in the 
I 
Table 17. The Cost-Related Outcome of Sedative-Hypnotic Administration. 
Cost of Administ~ation for Study Patients (n = 87) 
Cost ($)b 
Patients days/ Cost/pt. day 
12 weeks (¢) 
Pre Post Pre Post Pre Post 
Administered 32. 33 32.20 7308 7309 0.44 0.44 
Bi11edc 22.79 28.70 7308 7308 0.31 0.39 
Lossd 0. 13 0.05 
a~1ean monthly census = 778 (December 1975, January 1976, and February 1976). 






1249. 50 1249.50 
880.31 1107.50 
369.19 142.00 
cTabulated from the computerized billing value indicated for each drug order on t he patient 
medication record a~d based upon reimbursement of the Medi-Cal Drug Formulary. 




Table 18. Incidence of Repeat SH Doses Administered. 
Pre-Study 
Post-Study 















effectiveness of the agent(s) to induce sleep. 52 · 53 The pre-study 
results show that about 18% of the patients received daily SH administra-
tion. In addition, the administration of daily SH agents can be assumed 
to comprise the major portion of the total SH expenditure. It can be 
estimated that decrease in the number of orders administered daily by 
half would reflect an approximate 30% savings in total SH costs per year. 
Therefore, emphasis should be made to decrease the chron ic daily admin-
istration of SH agents. Additionally, unnecessary daily administrations 
could be decreased by writing all SH orders (excluding phenothiazines) 
as PRN. This wculd help eliminate situations where nurses administer the 
hypnotic each night, not necessarily due to patient needs, but because 
the order is not written as PRN. 
Choice of Aoent _ __:.._____,.___ 
Although flurazepam is currently considered a drug-of-choice for 
chronic hypnotic use due to its lower toxicity and greater safety in 
potential drug overdose,67 ,68 its administration cost may be a factor 
of greater practical value to LHH. This expense was related pri marily 
to its exclusion from the ~1edi-Cal drug formulary. At the time of 
this study no attempts to claim payment for its administration were 
being made. These methods could include contact and payment by the 
patient's responsible party or the initiation of the Medi-Cal Treatment 
Authorization Request (TAR) for each flurazepam order. The TAR approval 
is justifi ed by demonstration that other SH agents have been tri ed and 
shown to be ineffective, or created a dependence liabi lity or caused 
a hyper sensitivity reaction. However, the ti me expense to implement 
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these methods may be greater than the actual administration expense of 
the drug. The acquisition cost for flurazepam 30mg is 5 times greater 
than its closest alternative, chloral hydrate 500mg. Therefore, if 
this cost factor were felt to be of significant importance , then flura-
zepam prescribing should be recommended for special situations only. 
Unspecified PRN Orders for Diphenhydramine 
Diphenhydramine is not considered a traditional hypnotic agent and 
is often prescribed PRN for rashes or allergies in addition to insomnia. 
Pre-study results show that 23% (3/13) of the diphenhydramine PRN orders 
were prescribed without a specific indication. Its use as a PRN seda-
tive for insomnia should be specifically stated in order to eliminate 
possible confusion to the nursing staff regarding the prescribed purpose. 
This would reduce its admi nistration for unintended purposes and would 
comply with Title 22 regulations68 which state that PRN orders must be 
accompanied with a specific intent for administration. 
Interventions 
Physician Interventions 
The SH OUR results were presented to a combined medical staff -
~1AUR Committee conference during week 1 of t he post-study period (Fig-
ure 1). The attendance at the conference included 19 of 22 LHH phys i-
cians, including the Medical Director and clinical pharmaco logist/ 
internist. The handout of t he SH OUR results was given to the physicians 
along with a list of the SH agents contained in the Medi -Cal drug Formu-
lary (see Appendix D).h The ent ire presentation and discussion lasted 
hThese data reported in the SH OUR Handout. 
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about 30 minutes. i 
The discussion regarding routine SH administration was not accom-
panied by much discussion or apparent concern. One physician, noting 
the data regarding PRN administration, stated that since 3/4 of the SH 
orders were not given, there was no significant administration problem. 
It was felt that the administration of SH agents was perceived by most 
physicians as a nursing responsibility. The question as to whether 
sleeping pills were really needed was di scussed and generally voiced as 
a nurse judgment. The discussion concerning the cost factors of flura-
zepam administration also failed to create considerable discussion, 
however, it was felt that the cost aspects, in general, were understood 
by the physicians. The same impression was felt regarding the non-
specific prescribing of diphenhydramine. Other than the discussion 
which followed the SH OUR presentation, no organized recommendations or 
agreements were made. 
A totally separate, uncontroll ed intervention, the physician ward 
rotation, occurred in week 6 of the post-study period and involved 17 
of the 18 wards in the project. 
Nurse Interventions 
The results and problem areas of the Sll OUR study v1ere discussed 
by the author ~;-lith the head ward nurses during week 10 of the post-study 
period (see Figure l).j Attending the di scussion were 14 of 25 head 
;The LAX OUR study was presented to the physicians immediately 
following. 
jThe SH and LAX OUR studi es were al so presented at this discussion. 
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nurses. A tape recording was made by the nursing inservice director 
for the nursing supervisors and other head nurses unable to attend the 
discussion . The entire discussion was approximately one hour long . 
See Appendix F for an outline of the discussion. 
In general, the head nurses appeared to understand the problem 
areas presented. The problem of routine administration of SH agen~s 
seemed to be agreed by the nurses, and this information was to be com-
municated to the evening staff administering the SH agents. While 
flurazepam prescribing was primarily a physician related problem, it 
was agreed that the head nurses would try to discourage its prescribing 
to the physicians whenever possible. The confusion created by unspeci-
fied PRN orders for diphenhydramine was known, and any such orders 
made in the future were to be corrected. Overall, the di scussion was 
positive and a genuine enthusiasm from the nurses present was fel t. 
The low attendar.ce, approximately half of the head ward nurses, may 
have been a hindrance to the actual impact of such an intervention. 
The attendance and comprehension of the tape recording for those absent 
was not obtained and consequently its impact i s uncertain. 
Post-Study Results 
The success of the interverttions was measured immedi ately following 
their implementation and wa s shown as the two time periods (week 1-5, 
week 6-13) of the post-study. It is obvious that each of the time periods 
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are not independent of each other and that there was possible carryover 
influence in the second period from the first. Nevertheless, these time 
periods do attempt to detect the short-term impact of each intervention(s). 
In some cases, changes appeared to be linked to a specific intervention, 
although other changes are probably due to the effects of multiple inter-
ventions. 
Demographic Data 
The patient population at the completion of the post-study period 
was 87 (40 female and 47 male). Dropout patients included 27 expired 
(17 female and 10 male) and 16 transfers (8 female and 8 male) from LHH. 
Patient deaths were assumed to be natural and causal link between the 
expir·ed patient group and a particular drug therapy \'tas not persued. 
The average patient in this study was 77 years of age, male and 
caucasian (Table 19). The chronic diagnoses reported in the patient 
histories (Table 20) showedan average of 2.6 diagnoses per patient. This 
agrees with that reported by Hood50 (3.1) a~d Taylor31 (3.0). The most 
common diagnoses, occurring in nearly one-half of the patients, was 
arteriosclerotic heart disease and chronic brain syndrome . This is simi-
lar to that reported by Hood. 50 Approximately 20% of the patients had 
histories of chron ic al coholism which may be related to the larger male 
population and the locale of the hospital. 
Distribution 
A noticeable decrease in SH prescribing was observed following 
the head nurse discussion/physician rotation (Table 12). This change 
was statistically significant (See Prescribing Decisions - All SH Agents). 
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76.9 







Table 20. Sedative-hypnotic and laxative demographic data: Percent 
distribution of the various chronic diagnoses per total 
patient population (N=87). 
Mean number of diagnoses/pt. 2.6 
Range 1 - 5 
Arteriosclerotic heart disease 
& hypertension 






Chronic obstructive pulmonary disease 
Arthritis 



















The number of SH agents per patient (Table 13) showed a similar decrease 
by the end of the post-study period. 
The individual agents (Table 14) showed a slight decrease in 
flurazepam prescribing following the medical staff conference (week 1-5) 
and a similar decrease for diphenhydramine following the head nurse con-
ference/physician rotation (week 6-13). These trends are evaluated sta-
tistically in the following discussion of prescribing decisions. 
Prescribing Decisions -All SH Agents Combined 
The methods of evaluating physician prescribing decisions are 
discussed in the Methods. It should be noted that the duration (in 
weeks) of the various time periods were not the same and can theoretically 
effect the total number of possible prescribing decisions made. The 
longer time periods allow for a greater number of physician visits and con-
sequently a greater chance for prescribing changes. In this evaluation, ' 
the pre-study period contained the greatest number of v1eeks ( 12) compared 
to the 5 \'leek and 8 vteek time periods during the post-study. 
A greater occurrence of both new and discontinued SH orders during 
the post-study period was noted (Figure 10). Increases in both new and 
discontinued orders followed the physician conference (week 1-5) and a 
greater, but similar increase following the head nurse discussion/physician 
rotation (week 6-13). The increases in path new and discontinued orders 
appears to suggest that physicians were changing SH regimens (ie. a 
discontinued order followed by a new order) rather than either discontinu-
ing or starting SH therapy. 
The statistical evaluation of this data is shown in Tables 21 and 
22. A very significant difference (P < O.OOl) v1as observed v1hen the 
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Figure 10. Prescribing Decisions for All SH Aqents During Pre- and Post-Studies. 
a~1edica1 Staff Conference on wk 1. 























~ No change in 
drug order 




4-- Pre-Study d=72 ~ 
D New drug order 
d = Total number of 
decisions 
Vvk 1-5° Wk 6-13b 




Table 21. Evaluation of Physician Prescribing for All Sedative-Hypnotic Agents. 
Prescribing Decisions 
Time Period No Change Discontinued New Order 
Pre-Study 
wk 1 - 12 61 0 1 
Post-Study 
wk 1 - 5a 63 5 3 
wk 6 - 13 b 54 12 9 
Chi -Square 2 = 20.25/4 df p < 0.001 X 
·aMedical staff conference on SH drugs and presentation of study data was made on wk 1. 




Table 22. Evaluation of Physician Prescribing for All Sedative Hypnotic Agents. 
Time Period 
Pre-Study 
wk 1 - 12 
Post-Study 
wk 1 - sa 
Pre-Study 
wk 1 - 12 
Post Study 
wk 6 - 13b 
Post-Study 
wk 1 5 





Chi-Square x2 = 5.45/2 df p > 0.05 
61 
54 
Chi-Square x2 = 17.75/2 df p < 0.001 
63 
54 















aMedical staff conference on SH drugs and presentation of study data was made on wk 1. 




pre-study period and both time periods of the post-study were compared. 
Pair-wise comparisons between the various time periods were also tested 
to determine which periods might be responsible for the significant 
prescribing changes. The period following the head nurse discussion/ 
physician rotation (week 6-13) was significantly different (~ < 0.001) 
from both the pre-study and week 1-5 of the _post-study period. This 
difference appears to be attributed to a change in SH agents which could 
be expected from a rotation of ward physicians. 
Prescribing Decisions - Individual SH Agents 
An evaluation of each SH agent for changes in prescribing decisions 
was done to identify which SH agents were responsible for the significant 
changes discussed above. 
A significant decrease in diphenhydramine prescribing (~ < 0.05} 
occurred following the head nurse discussion/physician rotation (Figure 11~ 
Table 23). Additionally, new diphenhydramine orders occurred in this 
same ti me period although not statistically significant (£ > 0.1). These 
findings may suggest that there is considerable disagreement among physi-
cians regarding the prescribing of diphenhydramine for sleep observed most 
noticeably following a physician rotation. 
Chloral hydrate (Figure 12), while showing some discontinued orders 
' 
follo~1ing the medical staff conference and both new and discontinued 
orders following the head nurse discussion/physician rotation, did not 
shov.' a significant decrease from the pre-study period (£ > 0.05 ). Flura-
zepam (Figure 13) showed similar trends as for chloral hydrate and also 
failed to show a significant decrease (£ > 0.5). 
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Figure 11. Prescribing Decisions for Diphenhydramine During Pre- and Post-Studies. 
Pre-Study = wk 1 - 12; 
Post-Study= wk 2 - 13; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 
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Figure 12. Prescribing Decisions for Chloral Hydrate During Pre- and Post-Studies. 
Pre-Study = wk 1 - 12; 
Post-Study = wk 2 - 13; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 
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Figure 13. Prescribing Decisions for Flurazepam During Pre- and Post-Studies. 
Pre-Study = wk 1 - 12; 
Post -Study = 1~k 2 - 13; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 
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Table 23. Statistical Analysis of Decreased Sedative-Hypnotic Prescribing. 
Category 
Diphenhydramine 
wk 1 - 12 
Pre-Study Post-Study 
No Change & Compared No Change & 
New Order Discontinued to 
13 0 wk 1 - sa 
wk 6 - 13b 






p > 0.1 
p < 0.05 
Chloral hydrate, flurazepam, diazepam and thioridazine showed no significant decrease {p > 0.05) 
during the period of study. 
aMedical staff confer2nce on SH drugs and presentation of study data was made on wk 1. 





A summary of chloral hydrate, flurazepam and diphenhydra~1ine admin-
istration (Figure 6) shows that the post-study results appeared propor-
tional with the decrease in SH orders previously mentioned. 
Chloral hydrate administration ( Figure 7) showed a slight increase 
in the average value for those orders not administered each week and a 
decrease in those administered daily over the post-study period. Statis~ 
tical evaluation (Table 24) demonstrated a significant difference between 
th~ pre- and post-study periods (£ < 0.05) and within the post-study 
itself(£< 0.01). This difference was related, in part, to a decrease 
in routine administration in the post-study period. 
Flurazepam and diphenhydramine administration are represented 
in Figures 8 and 9. Both show similar pre- and post-study results. How-
ever, flurazepam administration was significantly different (£ < 0.05) 
bet\'leen the pre- and post-study periods (Table 25). This differen c-e may 
have been due to a decrease in routine administration and an increase in 
orders not administered during the post-study. 
~on-specifi~ Prescribin[ 
The writing of diphenhydramine PRN orders (Table 16) showed that 
the nonspecified orders were corrected prior to week 0. Thi s prescribing 
problem was known by the nursing staff, primarily from state regulations, 
and had previously examined through nursing audits. These specific 
interventions implemented by the nursing department were presumably 
responsible for these results. 
I . I I 
Table 24 . Frequency of Chloral Hydrate PRN Administrat ion . 
Frequency of 
Hee kly 
Administrations wk 1-4 
Not Administered 102 
Less Regular a 7 
More Regular b 14 
Administered Daily 45 
Chi-Square 
Pre- and Post -Study (4x6) 
Pre-Study only (4x3) 
Post-Study only (4x3) 
aAdministered 1 - 3 times per ·week . 
bAdmi ni stered 4 - 6 t imes per week . 
Total of Weekly Administrations 
Pre-Study Post -Study 
wk 5-8 wk 9-12 wk 2- 5 wk 6-9 
105 109 110 101 
11 10 2 10 
6 4 1 9 
47 44 41 33 
X 
2 = 30.30/15 df p < 0.05 
'2 
8. 26/6 df p > 0.1 X = 













Net Administered 41 
L~ ss Regulara 3 
M9rE; Reguiarb 0 
Administered Daily 4 
Chi-Squarec 2 = 7.54/2 df X 
aAdministered 1 - 3 times per week. 







p < 0.05 
Tot al of Weekly Admi nistrat ions 
Post -Study 
wk 9- 12 wk 2- 5 wk 6-9 
39 33 39 
4 8 5 
l 1 l 
4 3 l 
c3x2 analysis by combining "less regul ar" and "more regul ar" categor ies and using 12 week 











. The cost analysis of the SH group (Table 17) showed that the cost 
of administration was virtually the same for both the pre- and post-study 
periods. The billing value, however, did increase for the post-study 
period. This increase resulted in an estimated 18% sav ings to LHH and 
may be related to the decrease in routine flurazepam administration. 
Patient Outcome 
The incidence of repeat doses increased during the post-study 
period (Table 18). In contrast, the number of patients receiving repeat 
doses decreased from 5 in the pre-study to 4 in the post-study. This 
increase in repeat doses was associated with one patient who received 
41 repeat doses during the post-study period. In light of this excep-
tion, no noticeable change in patient outcome occurred between pre- and 
post-studies. 
DISCUSSION 
The extensive use of SH agents in the acute65 ,70 and 1ong-term50 
hospital setting is well documented and is supported in this study by 
the high prevalence of SH prescribing. This appears to be related to 
the practice of standing SH orders in the institutional setting. One 
reason might be that the "\~ashington Manual," 71 a therapeutic manual 
carried in the coat pockets of many physicians in training, does not 
discourage this prescribing practice. 
The probl em here is not the action of these drugs to treat insomnia 
but rather physici an prescribing in situations where there is an inade-
quate evaluation of their need. Several factors promoting routine 
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prescribing include: (1) physician convenience, ie ., the physician does 
not want to be bothered to make a drug order if and when insom~ ia develops; 
(2) nurse convenience, ie., the nurse does not want to bother the phys ician 
for an SH order; and (3) the intent of the nurse and/or physician to make 
the patient conform to the hospital environment. This last factor may be 
in violation of Federal Regulations13 which do not permit the restraint 
of patients by force or medication. Whether the use of SH drugs i~ this 
fashion is considered a restraint has not been legally defined at this 
time. 
The high frequency (72%) of SH orders not administered in this 
study further documents the questionable need of SH agents in SNFs. A 
few physicians at the medical staff conference on SH agents concluded this 
finding as "no real probl em" as long as the majority of these drugs are 
not being given. While this is generally correct on a toxicological 
bas i s , it may be important to consider the cost aspects of a drasfically 
over-supplied situation.k The cost to supply these agents as a standing 
order for long-term care patients, when extrapolated to the U.S. nursing 
home population, can be very costly when in actuality the majority of 
them are not being administered by the nursing staff. If only half of 
the routine orders were eliminated, the dollar savings in only pharmacy 
professional fees annually could be very substantial. This savings 
kThe supply of these agents to SNFs differs from the acute care 
setti ng in that, in general, a 30 day supply must be di spensed for each 
SH order. Further, Federal DEA laws for controll ed drugs do not permit 
the return of these agents to the pharmacy for credit of unused dosage 
units when di scontinued. They must be destroyed in the SNF. Consequently, 
the supp ly of these agents on a routine basis involves the di spensing of 
a 1 arge number of dosage units a 1 ong with a pharmacy dispensing fee for 
each SH order regardless of its administration. 
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would directly benefit the Medicaid prescription expenditure which sup-
plies SH agents to its patients on an unrestricted basis. 
The follow-up results of the M.D. conference (week 1-5) failed to 
have a statistically significant impact upon physician prescribing. This 
failure was felt to be primarily related to an inadequate discussion of 
routine prescribing of SH agents at the conference. At the time of the 
conference, this was not considered a major problem and consequentlj was 
not emphasized to the physicians. 
Additionally, flurazepam prescribing failed to change significantly 
following the physician conference, in light of adequate discussion time. 
It was felt, in this situation, that the emphasis of cost aspects of 
f lurazepam prescribing did not facilitate physician acceptance of the 
problem. Other investigators such as Miller43 also failed to show an 
impact on hypnotic prescribing through the distribution of a therapeutic ' 
bul l etin on hypnotic drugs. May, Stewart and Cluff44 did document a 
change in prescribing when certain SH agents were temporarily unavailable 
from the pharmacy. However, this was only a substitution of agents versus 
an overall decrease in prescribing frequency. In light of this, SH 
prescribing habits appear to be difficult to change. 
Following the head nurse discussion/physician rotation were trends 
for both new and discontinued SH orders . For exampl e, diphenhydramine 
showed slightly more discontinued orders over new orders, wh il e chloral 
hydrate and flurazepam both showed about equal increases in both pre-
scribing decisions. The tv10 interventions occurring at the beg inning of 
this time period made it diffi cult to determine which or both influenced 
these prescribing changes. Considering that the head ward nurse di scuss ion 
106 
emphasized the same problem areas as that in the medical staff conference, 
one would expect a general decrease in SH prescribing or incre~se in 
discontinued orders. The occurrence of both increased new and discon-
tinued SH orders could be explained more likely through the rotation of 
ward physicians. This effect of a 11 fresh look 11 of a new physician upon 
the chronic drug orders of the previous physician appears to create 
prescribing changes especially when each physician probably prescribed 
a favorite SH agent as a routine order. This phenomena is further exempli-
fied by the significant decrease (P < 0.05) in diphenhydramine prescribing 
which occurred after the physician rotation. This is probably related to 
the fact that diphenhydramine prescribed for sleep is not considered a 
traditional SH agent by most physicians. 
Unpublished data collected at LHH studied this prescri bing influ-
ence regarding psychotropic prescribing and concluded that those patients r 
receiving a new physician were more likely to have their psychotropic 
drugs decreased or discontinued than those patients retaining the same 
physician. Whether this reflects an attitudinal change in prescribing, the 
impact of forced awareness or other factors is uncertain. Further con-
trol led study of this influence is needed to determine more clear-ly the 
dependent factors. 
Turning t oward PRN administration of SH agents , which was primarily 
a nursing decision, the implementation program focused upon routine 
administration. Pharmacologically, the development of tolerance and 
decrease in efficacy of routine admini stration of SH agents is well 
known52 , 53 and is explicitly discouraged in the AMA Drug Evaluat ions 
which states 11 The $edative-hypnotics should not be admini stered continuously ... 
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since the effectiveness of most sedative-hypnotics is reduced by the 
second week of continual administration . "72 This problem area is particu-
larly prevalent in the SNF setting. Approximately 25% of SH orders were 
administered nightly in this study with very few orders administered 
intermittantly (less regular or more regular). This suggests that the 
nurse administration of SH agents will generally fall into a repeated 
administration pattern. This PRN administration pattern can easilY be 
perpetuated by the following practices. First, SH PRN medication can 
often be administed in a "copy-cat" manner determined by the previous 
night's administration. This pattern can lend itself to chronic adminis-
tration without proper assessment of the patients' needs for each dose. 
Ultimately, a psychological dependence to purely receiving the tablet or 
capsule each night may develop. In this situation, the patient requests 
the medication when it is not offered, regardless of the need or action 
of the drug. This is hypothetical but can easily occur with elderly 
patients. Another practice supporting routine administration is the 
prescribing of SH agents without a PRN order. This practice is also 
enhanced by Title 2268 requirements in California which states that each 
PRN dose administered must be documented by the nurse in ~witing as to 
reason and its subsequent result. Hence many SH orders are purposely 
changed (per nurse request) to a non-PRN order to eliminate this time 
consuming practice. Here again, routine administration of SH agents is 
perpetuated. To remedy this practice, perhaps all SH doses administered 
should be required to be documented by the nurse to promote the assessment 
of patient need for each dose. A final practice which may have contri-
buted to routine SH administration is the elderly pati ent being psycho-
logically dependent on taking the green or red capsule each ni ght, or 
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11 pill taking compulsiveness. 11 This situation best lends itself to the 
trial of a placebo with special nursing intervention to 11Wean 11 the patient 
from the nighly SH. Further research into this area is needed , especially 
with institutionalized elderly patients. 
The post-study results demonstrated a statistical ly significant 
change in the PRN administration of chloral _hydrate and flurazepam. A 
decrease in the routine administration of both of these agents was · 
observed following the head nurse discussion/physician rotation (week 6) 
and may be responsible for the significant administration changes . Fur-
ther, the fact that neith~r of these · two agents demonstrated statistically 
significant changes in their prescribing over this same time period sug-
gests that their administration does vary through nurse decisions. This 
was only a nurse related intervention for SH agents and reli ed upon the 
head nurse to convey the information to the even ing shift nurses admin-
i stering the SH agents. Whether a specific inservice on SH agents with 
the evening shift nurses would have had a further impact on SH adminis-
tration is not known and needs to be further investigated. 
In summary, the major impact of the interventions related to SH 
PRN administration. The discussion of the DUR study with head ward nurses 
appears to be an effective method affecting SH admini stration. It is 
impo rtant to consider the presence of the author in the wards following 
the interventions as pass ive reinforcement. Thi s may have enhanced the 
impact of the head nurse discussion. 
In contrast, the medical staff conference failed to show an 
immediate impact on SH presc ribing . This may be due to the lack of 
importance of cost/benefit prescribing as opposed to the prescribing of 
11 favorite 11 SH agents. 
LAXATIVE RESULTS AND DISCUSSION 
Pre-Study Results 
The results of the initial utilization study, referred to as the 
LAX OUR study, indicate problem areas associated with LAX therapy which . 
were identified. In terms of implementing changes, these problems 
related primarily to nursing decision because of their influence in 
selecting LAX regimens. A description of these results will follow 
along with the spec ific problem areas identified . 
Distribution 
Ninety percent (78/87) of the patients in the study were prescribed 
at l east one laxative in week 1 of the pre-study period (Table 26) . This 
percentage fluctuated only slightly for the 12 week period. Seven~-four 
percent of the patients were prescribed ei ther one or two agents, 13% 
were prescribed three, 3% four and 10% were not prescri bed any agents 
(Table 27). Bisacodyl, nearly all as the suppository form, and saline, 
all as milk of magnesia, were the two most frequently prescribed LAX 
categori es , 40% and 39% of the patients respectively (Tabl e. 28). Both 
agents did not show much change during the pre-study period . The stool-
softening agents showed the most change in prescribing frequency; 24.1 % 
in week 1 and only 20.7% at the end of t he pre-study. 
LAX Administration 
The frequ ency of PRN admi ni str3tion is graphed for each LAX cate-
gory in Figures 14 to 19. The values reported are averages (with standard 
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Table 26. Prevalence of Patinets (N=87) Prescribed Laxative(s). 
Percentage 
Pre-Study Post-Study 
wk 1 wk 12 wk 0 wk 4a wk 9b wk 17c 
89.7 88. 5 88.5 87 .4 78.2 79.3 
ai nservice education to nursing staf f (including advocation of dietary 
bran use) was presented on wk 1. 
bMedical staff conference on LAX agents and presentation of study data 
was made on wk 5. 
cHead nurse discussion on LAX agents and a physician ward rotation 
occurred on wk 10. A memorandum from the Director of Nursing con-
cerning the use of bran was distributed on wk 11. 
--0 
' 
Table 27. Percent Distribution of Laxatives Prescribed per Patient (N=87). 
Percentage 
No . of Pre-Stud,t Post -St ud,t 
LAX/pt wk 1 \'lk 12 wk 0 wk 4a wk 96 wk 17c 
None 10.3 11.5 11. 5 12 .6 21.8 20. 7 
One 35.6 34.5 37 .9 36.8 39.1 39 .1 
Two 37 . 9 36.8 35 . 6 42 . 5 32 .2 34 . 5 
Three 12. 6 13.8 10 . 3 4.6 3. 5 4.6 
Four 3.5 3.5 4.6 3.5 3.5 1.2 
alnservice education to nursing staff (includ ing advocat i on of dietary 
bran use) was presented on wk 1. 
bMedical staff conference on LAX agents and presentation of study data 
was made or. wk 5. 
cHead nurse discussion on LAX agents and a physician ward rotation occurred 
on wk 10. A memorandum from the Di r ector of Nur s i ng concerni ng t he use of 
bran was di stributed on wk 11. 
---
--~ . I I I . 




LAX Category wk 1 wk 12 wk 0 wk 4a wk gb wk 17c 
Bisacody1 40.2 40.2 42 .5 41.4 36.8 44.8 
Saline 39.1 41.4 42.5 37.9 37.9 36.8 
Stool-Softeners 24 .1 20.7 20.7 21.8 20.7 16. 1 
Bul k-forming 20 .7 19.5 18.4 12.6 10.4 10.4 
Lubricant 19.5 20.7 16. 1 16. 1 5.8 4.6 
St imu lant 16.1 16. 1 13.8 11.5 10.3 9.2 
ainservice education to nursing staff (including advocation of dietary bran use) 
was presented on wk 1 . 
bMedical staff conference on LAX agents and presentation of study data was made 
on wk 5. 
cHead nurse Jiscussion on LAX agents and a physician ward rotation occurred on 
wk 10. A memorandum from the Director of Nursing concerning the use of bran 
was distributed on wk 11. --N 
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Figure 14. LAX Administration for Bulk-Forming Agents during Pre- and Post-Studies. 
Pre-Study= wk 1 - 12; 
Post-Study= wk 6 - 17; 
Vertical bars = +1 Standard Deviation 
aAdministered 1 - 3 times per week. 

























































Figure 15. LAX Administration for Stool-Softening Agents During Pre- and Post- Studies. 
Pre-Study= wk 1 - 12; 
Post-Study = wk 6 - 17; 
Vertical bars = +1 standard dev·iation. 
aAdministered 1 - 3 times per week. 










































Figure 16. LAX Administration for Biscodyl During Pre- and Post~studies. 
Pre-Study ~ wk 1 - 12; 
Post-Study ~ wk 6 - 17; 
Vertical bars ~ +1 Standard Deviation. 
aAdministered 1 - 3 times per week. 











































Figure 17. LAX Administration for Saline Agent Durinq Pre- and Post-Studies. 
Pre-Study = wk 1 - 12; 
Post-Study= wk 6 - 17; 
Vertical bars = +1 Standard Deviation. 
aAdministered 1 - 3 times per week. 






























































Figure 18. LAX Administration for Stimulants (excluding bisacodyl) During Pre- and Post-Studies. 
Pre-Study wk 1 - 12; 
Post-Study = wk 6 - 17; 
Vertical bars = +l Standard Deviation. 
aAdministered 1 - 3 times per week. 









































Figure 19. LAX Administration for Lubricant Agents during Pre- and Post-Studies. 
Pre-Study = wk 1 - 12; 
Post-Study = wk 6 - 17; 
Vertical bars = +1 Standard Deviation. 
aAdministered 1 - 3 times per week. 










































deviation) for both 12 week study periods. The "total" value denotes the 
weekly sums of all four administration frequencies. 
Bulk-forming (Figure 14) and stool-softening (Figure 15) agents 
were primarily administered daily as would be expected in order for them 
to exert "laxative" action . In contrast, bisacodyl (Figure 16), saline 
(Figure 17) and stimulant (Figure 18) agents were generally administered 
less regularly or not at all. Lubricant (Figure 19) showed both routine 
and less regular administration patterns. 
Non-specific Prescribing 
Approximately 20% of the patients had a "laxative-of-choice" (LOC) 
or "bowel routine" order (Table 29}. 
Cost Outcome 
A cost of 3 cents per patient-day was determined from pre-study 
data (Table 30). This was estimated to result in a $10,000 annual expense 
for LAX administration at LHH. 
Patient Outcome 
Thi s parameter of LAX therapy was initially planned to be followed 
vi a the frequency of fecal imp~ctions or the incidence of loose stools. 
It was noted at the initiation of the pre-study that the collection of 
these types of data in the wards was impractical. This was due to the 
questionabl e accuracy of the recording of these parameters in the charts. 
A specifically designed study to evaluate these outcomes would be neces-
sary. Consequently, these data were not coll ected dur ing the pre- or 
post-study periods . 
, / 
Table 29. Frequency of Patients (n=87} Prescribed a "Laxative-of-Choice" 
or "Bowell Routine" Order. 
Pre-Study 
wk 1 wk 12 wk 0 
19 15 4 
(21.8%) (17.2%) (4 .6%) 
Post-Study 
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Table 30. Cost-Related Outcome of LAX Administration . 












aMean census = 778 (December 1975, January 1976, February 1976). 
bBased upon the .acquisition cost to the LHH pharmacy for each LAX agent. 
Extrapolation to Cor-









Excessive Prescribing and Use of LAX Agents 
Virtually all patients had orders for a laxative(s), even though 
it has been emphasized recently by gastroenterologists that the addition 
of 8-12 grams of fiber (usually bran) to the daily diet would serve as 
a preventative approach toward patient constipation. 
Additional savings to the hospital could be achieved if the 
availability could be limited to 1 - 2 agents per category according 
to the lowest acquisition prices. 
Use of Mineral Oil Preparation 
Mineral oil preparations, used frequently, are felt best reserved 
for occasional use. 73 
Non-Specific Prescribing 
The LOC order written by physicians can potentially be costly and 
possibly harmful from the standpoint that the nursing staff may not be 
aware of the most effective, safest and least expensive laxative options. 
Interventions 
Physician Interventions 
The LAX OUR study results were presented to a combined medical 
staff - MAUR Committee conference during week 5 of the post-study period 
(Figure 1). The attendance at the conference included 19 of 22 LHH 
physicians, including the Medical Director and clinical pharmacologist/ 
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internist. A handout of the LAX OUR study and a table of some LAX costs 
were given to each physician (See Appendix E). The entire presentation 
lasted about 45 minutesm and included considerable discussion of the 
problem areas and proposed recommendations. 
In general, the discussion on the excessive use and costs of LAX 
therapy was very enthusiastic among the physicians. The chronic use 
of stimulant LAXs was primarily acknowledged as a consequence of the 
111axative habit 11 instilled by tradition and folklore in elderly patients. 
The use of a fiber supplement in the diet appeared to be accepted as 
an alternative to the traditional LAX administration. While the use of 
bran was felt to be a nursing decision, physicians were generally vocal 
for allowing the nurses to initiate its trail. The use and possible 
complications of mineral oil preparations was not discussed to any great 
magnitude but was felt to be understood by the physicians. The same 
was observed for the problem of non-specific prescribing of LAX agents. 
At the conclusion of the conference, no specific agreements or recom-
mendations were made on an organized basis, but considerable interest 
in switching to bran was expressed. 
Nurse Interventions 
First, an inservice education presentation was provided to all 
licensed nursing staff during week l of the post-study period (Figure 1). 
mThe SH OUR study was presented to the physicians immediately 
before the LAX OUR study at the same conference. 
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The presentation was delivered twice for the morning and evening shift 
• 
nurses and lasted approximately one hour. A tape recording was made by 
the inservice director and played twice for the evening shift nurses. The 
total attendance was 132 staff nurses, 11 head nurses, two supervisors 
and one assistant director of nursing . The inservice emphasized "ideal" 
LAX administration and the use of dietary fiber (bran) given each morn- . 
ing in the patients• cereal (See Appendix G). A pre- and post-test 
examination was administered to all nurses at the inservice, including 
those listening to the tape recording. The exams were essentially the 
same in content. They attempted to assess the immediate knowledge re-
tained by the nurses from the lecture (See Appendix J). All three 
nursing shifts showed a very significant(~< 0.001) improvement from 
pre- to post-test scores. 
It appeared that a majority of the nurses expressed that bran 
administration had not been tried in their wards and were enthusiastic 
regarding its trial. 
To follow-up the use of bran, a ward survey was conducted by the 
author at the end of the post-study period (See Appendix I) . The survey 
showed that indeed dietary bran was used in the wards (94%)_ during the 
post-study and it appeared that a majority (75%) had started its use 
after the LAX inservice was completed. Only three wards stated that 
bran had been given prior to the LAX inservice. In addition, over one-
half (50%) stated that nearly all patients were receiving dietary bran. 
Secondly, the results and problem areas of the LAX DUR study was 
discussed by the author with the head ward nurses and nursing supervisors 
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during week 10 of the post-study period (Figure l).n Attending the . . 
discussion were 14 of 25 head ward nurses. A tape recording was made 
by the nursing inservice director for those unable to attend the dis-
cussion. The entire discussion was approximately one hour long. An out-
l ine of this discussion appears in Appendix F. A handout of cost com-
parisons of the most common agents used was distributed to the nurses . 
(See Appendix E) . This l ist was intended to impose an awareness among 
the nurses for the more expensive LAX agents used in the wards. 
In general, the discussion appeared to be met with very good 
acceptance and understanding of the LAX problem areas presented. The 
excessive use of LAX agents and both the pros and cons of the addition of 
bran to the patients• diet were discussed. Since the _prescribing of LAX 
agents was felt to be primarily influenced by the nurse, in particular 
the head ward nurse who usually communicates with the primary ward physi- ' 
cian each visit, their role in improving LAX therapy was particularly 
emphasized. The nurses appeared to be very concerned about the excessive 
costs of LAX therapy and the posting of the handout of LAX costs in each 
\<Jard was suggest ed. A very enthusiastic attitude \lias f elt from the head 
ward nurses at the end of the discussion. 
Lastly, a memorandum (see Appendix H) was distributed to the 
assistant directors of nursing, nursing supervisors and head nurses from 
the ONS on week ll (Figure l) encourag ing the substitution of bran for 
cathartics . 
nThe AC and SH OURs were also presented at this discussion. 
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Post-Study Results 
The success of the interventions was measured immediately follow-
ing their implementation and was shown as the three time periods (week 
1-4, week 5-9, week 10-17) of the post-study. It is obvious that each 
of the time periods were not independent of each other and that there 
were possible carryover influences in the second period and especially 
in the third . Nevertheless, these time periods do attempt to detect 
the immediate impact of each intervention(s). In some cases, changes 
appeared to be linked to a specific intervention. In other cases, these 
changes were not as clear and were probably due to the effects of mul-
tiple interventions. 
Di stribution 
LAX prescribing decreased following the medical staff conference 
(week 5-9) from 87% to 78% of the patients in the study (Table 26). Pre-
scri bing then showed a slight increase following the head nurse discussion/ 
physician rotation/DNS memorandum (week 10-17). No noticeable change was 
noted in these data fol lowing the nursing staff inservice (week 1-4). 
The number of LAX agen t s/pat ient decreased during the post-study 
period (Tabl e 27 ). Those pati ents prescribed three and four agents 
decreased most noticeably following the nursing staff inserv ice (week 1-4) 
and continued to decrease for the duration of the post-study. 
There were various changes in the types of agents prescribed (Table 
28 ). The prescribing of bulk-forming agents decreased primarily follow-
ing the nursing staff inserv ice (week 1-4) and stool-softening agents 
following the head nurse discussion/physician rotation/DNS memorandum 
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(week 10-17). Bisacodyl primarily increased in the final time period 
(week 10-17). Lubricant agents showed a substantial decrease following 
the medical staff conference. 
Prescribing Decisions - All LAX Agents Combined 
By the end of the post-study period (week 17) there was a consider- · 
able increase in both discontinued and new LAX orders, with the discon-
tinued orders about twice as frequent as the new orders (Figure 20). The 
discontinued LAX orders showed a consistent increase following the nursing 
staff inservice (week 1-4), medical staff conference (week 5-9) and head 
nurse discussion/physician rotation/DNS 1nemorandum (week 10-17) interven-
tion periods. The new LAX orders increased only following the final 
intervention period. These changes were very significant (£ < 0.001) 
when the pre-study period and three post-study periods were tested 
(Table 31). 
Further comparisons (Table 32) showed that very significant changes 
occurred following the medical staff conference (£ < 0.001) and following 
the head nurse discussion/physician rotation/DNS memorandum (£ < 0.001). 
It appears that different LAX prescribing trends occurred in these two 
periods. The change following the medical staff conference was clearly 
attributed to the increase in di scontinued orders. The change occurring 
in the final intervention period (week 10-17) was not only attributed to 
an increase in discontinued orders, but al so new orders as well. 
A very significant change (£ < 0.001) was also observed within the 
post-study itself (Table 33). Additionally, each of the post-study 
intervention periods were significantly different when pair-wi se compari-
sons we re tested (Table 34). 
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Figure 20. Prescribing Decisions for All LAX Agents During Pre- and Post-Studies. 
aNursing Staff inservice on wk 1. 
br~ed i ca 1 Staff Conference on wk 5. 
cHead \~ard Nurse Discussion and Physician Ward rotation on wk 10; 
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Table 31. Evaluation of Physician Prescribing for All Laxative Categories. 
Prescribing Decisions 
Time Period No Change Discontinued New Order 
Pre-Study 
wk 1 - 12 137 5 
Post-Study 
\'/k 1 - 4 a 128 10 
wk 5 - gb 110 22 
wk 10 - 17c 95 16 
Chi-Square 2 X = 47.75/6 df p < 0.001 
ainservice education to nursing staff (including advocation of dietary 
bran use) was presented on wk 1. 
bMedica1 staff conference on LAX agents and presentation of study data 





cHead nurse discussion on LAX agents and a physician ward rotation occurred 
on wk 10. A memorandum from the Director of Nursing concerning the use of 





Table 32. Evaluation of Physician Prescribing for All LAX Categories . 
Prescribing Decisions 
Time Period No Change Discontinued New Order 
Pre-Study wk 1 - 12 137 5 5 
Post-Study wk 1 - 4a 128 10 4 
Chi -Square 2 = 2.00/2 df p > 0. 3 X 
Pre-Study wk 1 - 12 137 5 5 
Post -St udy wk 5 - 9b 110 22 1 
Chi-Square 2 = 15.66/2 df p < 0.001 X 
Pre- Study wk 1 - 12 137 5 5 
Post-Study wk 1 0-17c 95 16 '19 
Chi-Square 2 = 20 . 57/2 df p < 0. 001 X 
ainservice education to nurs i ng staff (including advocation of dieta ry bran use ) 
was presented on wk 1. 
bMedical staff conference on LAX agents and presentation of study data was made 
on wk 5. 
cHead nurse discussion on LAX agents and a physici an ward rotation occurred on 
wk 10. A memorandum from t he Director of Nurs ing concern ing t he use of bran 




Table 33. Post-Study Evaluation of Physician Prescribing for All LAX 
Categories. 
Prescribing Decisions 
Time Period No Change Discontinued 
wk 1 - 4 a 128 10 
wk 5 - gb 110 22 
wk 10 - 17c 95 16 





ainservice ~ducation to nursing staff (including advocation of dietary bran use) 
was presented on wk 1. 
bMedical staff conference on LAX agents and presentation of study data was made 
on wk 5. 
cHead nurse discussion on LAX agents and a physician ward rotation occurred on 
wk 10. A memorandum from the Director of Nursing concerning the use of bran 




Table 34. Post-Study Eva l ua t ion of Physician Prescri bing fo r All LAX 
Categories. 
Prescribing Decisions 
Time Period No Change Di sconti nued New Order 
wk 1 - 4a 
wk 5 - 9b 
Chi -Square X 
2 
wk 1 - 4 
wk 10 - 17c 
Chi-Square 2 X 
wk 5 - 9 
wk 10 - 17 
Chi -Square 2 X 
128 
110 
= 7. 37/2 df p < 0. 05 
128 
·95 
= 15. 55/2 df p < 0.001 
11 0 
95 













ainservice education to nurs i ng staff (includ ing advocat ion of dietary bran use) 
was presented on wk 1. 
bMedica1 staff conference on LAX agents and presentati on of study data was made 
on wk 5. 
cHead nurse discussion on LAX agents and a physician ward rotat ion occurred on 
wk 10 . A memorandum from the Director of Nursing concerning the use of bran 





While some of these post-study periods showed trends of greater 
discontinued LAX orders and others of new LAX orders being written, it 
appears that the physician and nurse directed interventions significantly 
altered LAX prescribing. 
Prescribing Decisions - Individual LAX Categories 
Bulk forming agents (Figure 21) showed a considerable number of 
discontinued orders following the nursing staff inservice (week 1-5). 
This decrease was statistically significant (£ < 0.05) as shown in 
Table 35. Additionally, no new bulk-forming orders were observed during 
the remainder of the post-study periods. 
Lubricant agents (Figure 22) showed a large decrease in prescrib-
ing following the medical staff conference (week 5-9} .. This decrease was 
very significant (£ < 0.001) as shown in Table 35. No new lubricant orders 
were observed during the remainder of the post-study period (week 10-17}. 
Sa line prescribing decisions (Figure 23 ) showed a noti ceable change 
following the head nurse discussion/phys ician rotation/ON$ memorandum 
(week 10-17). While both new and di scontinued orders were increased 
during this time period, only the discontinued orders were significant 
(£ < 0.05) from the pre-study values (Table 35}. 
Bisacodyl prescribing decisions (Fi gure 24) showed an increase in 
new orders occurring after the head nurse discussion/physician rotation/ 
DNS memorandum (week 10-17). This increase in bisacodyl prescribing 
was signifi cant (£ < 0.05) as shown in Table 36. 
The stimulant agents (Figure 25) and stool softeners (Figure 26), 
while showing trends toward decreased prescribing, did not demonstrate 
a significant change. ·' 
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Figure 21. Prescribing Changes for Bulk-Forming Agents During Pre- and Post-Studies. 
aNursing Staff inservice on wk 1. 
bMedical Staff Conference on wk 5. 
cHead \iard Nurse Discussion and Physician Ward rotation on wk 10; 
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Figure 22. Prescribing Decisions for Lubricant Agents During Pre- and Post-Studies. 
aNursing Staff inservice on ~1k 1. 
bMedica1 Staff Conference on wk 5. 
cHead Ward Nurse Discussion and Physician Ward rotation on wk 10; 
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Figure 23. Prescribing Decisions for Saline Agents During Pre-and Post-Studies. 
aNursing Staff inservice on wk 1. 
bMedical Staff Conference on wk 5. 
cHead Ward Nurse Discussion and Physician Ward rotation on wk 10; 
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Figure 24. Prescribing Decisions for bisacody1 (Du1co1ax ®) During Pre- and Post-Studies. 
aNursing Staff inservice on wk 1. 
bMedica1 Staff Conference on wk 5. 
cHead Ward Nurse Discussion and Physician Ward rotation on wk 10; 
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Figure 25. Describing Decisions for Stimulant Agents (excluding bisacodyl} During 
Pre- and Post-Studies. 
aNursing Staff inservice on wk 1. 
bNedical Staff Conference on wk 5. 
cHead Ward Nurse Discussion and Physician Ward rotation on wk 10; 
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Figure 26. Prescribing Decisions for Stool-Softening Agents During Pre- and Post-Studies. 
aNursing Staff inservice on wk 1. 
bMedical Staff Conference on wk 5. 
cHead Ward Nurse Discussion and Physician Ward rotation on wk 10; 
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Table 35. Statistical Analysis of Decreased Laxative Prescribing (by Category). 
Pre-Stud_y Post-Stud_y 
Decisions Decisions 
No Change & Compared No Change & 
Category New Order Discontinued to New Order Discontinued Significance 
Bulk-forming 
wk 1 - 12 17 1 wk l-4a 11 6 p < 0. 05 
wk 5-9b 9 2 p > 0.5 
wk 10-17c 9 0 p > 0.5 
Saline 
wk 1 - 12 36 0 wk 1-4 37 1 p > 0.5 
wk 5-9 34 3 p > 0.1 
wk 10-17 33 5 p < 0. 05 
Lubricant 
wk l - 12 18 0 wk l-4 14 0 p > 0. 5 
wk 5-9 5 9 p < 0. 001 
wk 10-17 4 1 p > 0.5 
Bisacodyl, stool-softeners and stimulants showed no significant decrease (p > 0.05) during the period 
of study. 
ainservice education to nursing staff (including advocation of dietary bran use) was presented in wk 1. 
bMedical staff conference on LAX agents and presentation of study data was made on wk 5. 
' 
cHead nurse disucssion on LAX agents and a physician ward rotation occurred on wk 10. A 
memorandum from the Director of Nursing concerning the use of bran was distributed on wk 11. 
<.11 
w 
Table 36. Statistical Analysis of Increased Laxative Prescribing (by Category) 
Category 
Bisacodyl 
wk 1 - 12 
Pre-Study 
Deci s ions 









No Change & 
Discontinued New Order 
wk 1 - 4a 
wk 5 - gb 





p > 0.5 
p > 0.5 
p < 0. 01 
Saline, stool-softeners, bulk-forming, lubricants and stimulants showed no significant increase 
(p > 0.05) during the period of study. 
ainservice education to nursing staff (including advocation of dietary bran use) was presented 
on wk 1. 
bMedica1 staff conference on LAX agents and presentation of study data was made on wk 5. 
cHead nurse discussion on LAX agents and a physician ward rotation occurred on wk 10. A memor-





LAX Administration 0 
Bulk-forming agents (Table 37) showed a decrease in administra-
tion, primarily from those orders administered daily, during the post-
study period. This change in bulk-forming administration was signifi-
cant Ce. < 0.05). 
Lubricant agents (Table 38) showed a very significant change 
(Q < 0.001) in administration. A decrease in the number of orders 
"administered daily" and "less regular" and an increase in "more regular" 
administrations was observed. 
The pattern of administration of the saline agent, milk of mag-
nesia (Table 39), appeared similar in both the pre- and post-studies, 
that is, predominantly not administered. Statistically, milk of mag-
nesia administration showed a significant change (Q < 0. 05) between 
both pre- and post-study periods . Further evaluation showed that this 
change only occurred in the pre-study (Q < 0.05). This demonstrated 
that the administration of milk of magnesia varied regardless of the 
LAX i~terventions implemented. 
Non-specific Prescribing 
The relatively high. frequency (22%) of LOC ordered documented 
in the pre-study period had considerably decreased prior to week 0 
of the post-study period (Table 29). The correction of this problem 
area before any LAX interventions were made was primarily due to the 
previous awareness of the problem by the DNS and Medical Director. 
Table 37. Frequency of Bulk-formi ng LAX Administrat ion. 
Frequency 
of vJeekly 
Administration wk 1-4 
Not Administered 11 
Less Regulara 2 
More Regu l arb 3 
Administered Daily 60 
Chi -Squarec X 
2 = 7.06/2 df 
aAdmin i stered 1 - 3 times per week . 







p < 0. 05 
Total of Weekl~ Admi nistrations 
Post -Studi: 
wk 9-1 2 wk 6-9 wk 10-13 
7 8 10 
0 0 1 
5 3 0 
60 33 25 
c3x2 analysi s by combin i ng "less regul ar" and 11more regular11 cat egories and using 12 week 




















wk 1-4 wk 5-8 




Pre- ar.d Post-Studies (4x6) x2 = 81.59/15 df 
Pre-Study only (4x3) 
Post-Study only (4x3) 
aAdministered 1 - 3 times per- \-:eek. 
bAdministered 4 - 6 times per week. 
2 X = 3.40/6 df 






p < 0.001 
p > 0.5 



















Table 39. Frequency of Saline LAX Administration. 
Total of Weekly Administrations 
Frequency Pre-Study 
of Weekly 
Administration wk 1-4 
Not Administered 130 
Less Regulara 11 
More Regularb 0 
Administered Daily 0 
Chi-Squarec 
Pre- and Post-Studies (2x6) 
Pre-Study only (2x3) 
Post-Study only (2x3) 
aAdministered 1 - 3 times per week. 
bAdministered 4 - 6 times per week. 






= 12.50/5 df X 
x2 = 7.88/2 df 
2 4.49/2 df X = 
Post-Study 
9-12 wk 6-9 wk 10-13 
118 111 111 
25 20 16 
1 2 0 
0 0 0 
p < 0.05 
p < 0.05 
p > 0.05 









Various on-going nursing audits were conducted during the pre;study 
period and were presumed to be responsible for the correction of this 
problem area. 
Cost Outcome 
The cost of LAX administration is shown in Table 30 and reveals 
a considerable decrease in the overall LAX costs during the post-
study period. A decrease in the cost per patient-day from 3¢ to 2¢ 
was estimated to reduce the LAX expense to LHH by nearly 50% of the 
pre-study estimate. 
DISCUSSION 
The excessive use, abuse and expense (over 250 million dollars 
annually) of laxative products has been well documented and all con-
tinued to show increases today. 74-76 Geriatric patients at·e lar~e 
users of laxatives because of the traditional emphasis on passing 
a soft stoo l daily, and consequently the 11 laxative habit 11 was ac-
quired.77 This phenomena is further evidenced by the unusua lly large 
number of LAX products available. Bowel consciousness has resulted 
in an increased popularity of l axati ve agents, and is supported by 
the advertis ing campa igns of the pharmaceutical industry which help 
reinforce t he misconception of the need for a 11 daily bowel movement . 11 
Thi s is further complicated by the public's lack of knowledge about 
the act ion of these agents and the factors affecting normal bowel 
function. 73 ,78 
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The impact of this is observed in the elderly by the increased 
incidence of the "cathartic colon" and induced bowel atony thought 
to be due to chronic misuse of stimulant laxatives. 77 In the condi-
tion of "cathartic colon," intestinal motility is absent due to the 
destruction of nervous innervation to the bowel and hence fecal 
elimination is dependent upon periodic exogenous stimulation. Milano77 
states that because a history of cathartic abuse is often obscure~ 
patients are often incorrectly diagnosed to have Addison•s disease, 
renal disease, hyperaldosteronism or granulomatus ileocolitis to cite 
a few. 
The elderly patient in the SNF, even though in an institutional 
setting, is not less susceptible to these complications as evidenced 
by the high rate of LAX prescribing documented in this study and 
elsewhere. 49 •50 The initiation of LAX orders in SNFs is influenced by ' 
physicians, nurses, and the patient (See Methods). These individuals, 
each with their favorite LAX products, help explain the extensive LAX 
regimens for many SNF patients. Exactly how many of these patients 
have the "cathartic colon" is uncertain. There is, presumably, a 
l arge number of these patients in \'Jhich the "laxative syndrome" 
can be avoided and the onset of chronic cathartic toxicity avoided 
through rational LAX use. 
The overall impact of the LAX OUR program was a significant change 
in prescribing and administration and considerable decrease in costs 
of LAX therapy at LHH. Considering the cost aspect of the program, 
an approximation of dollar savings on a national level can be roughly 
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projected. There are approximately 21.8 million people over the age of 65 
in the United States and reportedly only 5 percent are institutionalized, 
which results in approximately 1. 1 million SNF patients. l, 2 Based upon 
the cost of 3¢/patient-day, the estimated wholesale cost of LAX adminis-
tration in this population would be near 12 million dollars . Reducing the 
cost to 2¢/patient-day, as documented here , would result in a savings of 
4 million dollars per year. In California, the Medi-Cal drug formu-lary 
does not furnish LAX agents to their patients, therefore this savings would 
particularly benefit the individual SNFs which must supply LAXs for these 
patients. 
A major emphasis of the LAX OUR program advocated the use of dietary-
bran as an alternative to traditional LAX agents. The addition of 
efficacious amounts of bran to the patients• morning cereal would provide 
added bulk to the fecal material and ultimately elimi~ate the need for 
additional LAX administration. 
The current emphasis for increased roughage in the American diet 
has long been advocated by health food advocates and nutritionists for 
many years. 79 In addition, low fiber diets have been linked epidemio-
logically to the high prevalence of diverticular disease, irritable 
bo~>Jel syndrome and cancer of the colon. 80-82 The action of high dietary 
roughage i s reported to increase the frequency of bowel movements, 
decreased intesti nal transit time, and soften the stoo l s by retaining 
1-1ater in them. 73 Adverse effects of large amounts of dietary bran can 
include loose stoo l s and increase in both flatul ence and distension. 76 
Reports of adult osteomalacia, stunted growth and delayed puberty have 
been attributed to high fiber diets as evidenced in the Middle East, 
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India and Pakistan where unleavened bread is consumed. This is attributed 
to the capacity of the cellulose in the fiber to bind and prev~nt the 
absorption of calcium and zinc. 83 Another potential ri sk of bran use is 
esophageal and intestinal obstructions which are avoided by the consumption 
of large amounts of liquids. In addition, bran use may be contraindi-
cated in some patients with regional ileitis and ulcerative colitis. 84 
In perspective, the use of dietary bran monitored in the hospital setting 
is probably not a real problem in terms of patient complications and 
potential adverse reactions. 
At least three factors are important in assuring t he success of 
implementing a bran program. First is the need to gain the support and 
enthusiasm of the nursing staff. Secondly, if the bran diet is to be 
an effective substitute for LAX administration, the bran product must 
exert a pharmacological effect equivalent to that of the bul k-forming 
group . This concept is often overlooked and many times nurses wiN 
observe little effect from the bran supplement in which case an increase 
in the daily dosage is usually indicated. This explanat ion is often true 
for the failure of bran programs initi ated but di scont i nued because of 
lack of beneficial results . Raw-milled bran, which was used in this 
study , provides the highest gram weight of fiber whil e other processed 
bran cerea l s provi de fiber at about half the pot ency of the raw milled 
source. 84 The dose of bran must be individualized fo r each patient and 
i n thi s study one ounce of raw milled bran was the most common dose 
(see Appendix I), which provides approximately 3.0- 3.6 gm . of fiber. 84 
Thirdly , the bran suppl ement must be reasonably palatabl e or disgui sed 
to prevent pati ent rej ection. Here the bran was thoroughly mi xed into 
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the patient•s morning cereal and was generally well accepted by the 
patients. Other methods of introducing bran into the patients• diet can 
be in breads, cookies, muffins, etc. 
The use of dietary bran was advocated first in the nursing staff 
inservice (week 1) followed by the medical staff conference (week 5) and 
lastly at the head ward nurse discussion (week 10). It was very diffi-
cult to measure the number of patients receiving bran because its use 
was treated as a diet, natural food order as opposed to a medication 
order. The survey of head ward nurses at the end of the LAX post-study 
(see Appendix I) showed that most wards were administering bran to their 
patients and this was started following the intervention period. It 
must be mentioned, however, that the publicity of Dr. Rubin•s 11 Save 
Your Life Dietn, 79 which occurred near the time of this study, could have 
served as an external influence in the adoption of bran use in the wards. ' 
Other potential solutions to the overuse of LAX agents in the SNF 
setting were emphasized. 
First, rational, or 11 ideal, 11 administration of specific LAX agents 
was presented in both physician and nurse interventions. This included: 
less regular administration for stimulant, saline agents and bisacodyl; 
more regular or daily administration for bulk-forming and stool- softeners; 
and lubricant agents administered occasionally and only at bedtime. 73 
Secondly, the use of selected agents in each category based upon 
cost, would help alleviate the dollar impact of LAX overuse. A list of 
comparative LAX vJholesale costs was distributed to both physicians and 
head nurses at thei r respective presentations. 
Thirdly, the problem of national bowel conscious ne~s (i mpact of 
LAX advertising and belief of routine bowel movements) can contribute to 
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both the overprescribing and overgivi~g of LAX agents. An increase in 
the awareness of gastro-intestinal and normal bowel physiology was 
emphasized in the interventions. 
Conceptually, the methodology used in this DUR program is important. 
Achieving the acceptance of the nursing staff and physicians is the 
ultimate test of the success of such a program in the institutional 
setting. The hypothesis utilized here was the use of a LAX DUR study, 
aimed at identifying specific prescribing and administration problems and 
coupled wtih a pharmacist-directed implementation program directed toward 
the individual "problem" groups (ie. physicians, nurses, etc.), could 
effectively improve drug prescribing, administration, as well as a 
savings in LAX costs. The literature is replete with -advocates for the 
establishment of institutional DUR. 6,BS-BB However~ unl ess there is an 
implementation of a corrective phase measured by a follow-up study, DUR 
is an exercise in data collection. The overall results of the LAX post-
study here documents that when DURis used as a tool, it can be very 
powerful in achieving changes in drug use in this setting. 
Brodie, et a1, 85 states that 11 ... authority can assure continuity 
of support and resources for the DUR program. 11 This concept i s particu-
larly important when a pharmacy directed DUR is dependent upon physician 
acceptance. However, this "advocate," whether a physician or a committee, 
can also create disbelief if the 11 authority 11 is not respected by the 
particular physician(s). Speci fic physician advocates of the program · ·' : 
in the medi cal staff conference included the medical director and the : 
clinical pharmacologist/internist. They actively agreed to support the 
concepts of the DUR presented by the author a·nd pro vi de a co-factor ro 1 e 
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in facilitating physician acceptance . Their consultation and recommenda-
tions also assured a clear and sound scientific format for theoDUR. 
According to the investigation of Coleman, Katz and Mandell,40 the physi-
cian best accepts the experience or opinion of a colleague regarding the 
adoption of a new habit or practice. The medical staff conference con-
ducted here allowed for this interaction which further contributed 
to the physician acceptance of the LAX OUR study presentation. 
Another approach to physicians used in the medical staff confer-
ence was the treatment of 11 prescribing problems 11 as 11 hospital problems. 11 
OUR data can easily lend itself to the identification of 11 problem pre-
scribers11 related to a specific 11 prescribing problem. 11 However, in a 
presentation to a group of physicians this approach can potentially create 
antagonistic and protective feelings among all physicians and distract 
from the essence and value of the OUR study. This avoidance of an 
accusatory aspect of the OUR intended to de-emphasize drug prescr i"'bing 
to a hospital problem and allow for a neutral approach for the physician 
advocates. 
In summary, it is proposed that this methodology using the physi-
cian advocate and the non-accusatory, neutral appraoch of t he OUR allowed 
for a greater acceptance of information provided by the non-physician 
author. 
The remainder of this discussion will focus on the relative 
effectiveness of the interventions in causing a change in LAX utilization. 
The LAX post-study data showed that following the nursing staff 
inservice (week 1-4) there was a significant decrease (P < 0. 05) in bulk-
forming agents . This may reflect the initial trial of dietary bran on 
~ . . . . . ~ 
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certain wards in place of routine bulk-forming products. Further, since 
this intervention occurred prior to the physician intervention, this 
decrease in bulk-forming agents appears to document the influence of the 
nursing staff to effect drug prescribing for LAXs in this setting. The 
impact of the bran use on the bulk-forming orders remained for the 12 
weeks of the post-study, however, no assessment of the 11 lasting 11 effect was 
made. This is needed in order to help determine that the results observed 
were not due to the initial trial of bran. 
Another outcome of this LAX study is related to the use of mineral 
oil preparations. The post-study data shows the success of the medical 
staff presentation (week 5-9) in significantly (P < 0.001) changing physi-
cian prescribing of the lubricant group. It must be mentioned that the 
problems of the use of the mineral oil preparations was presented and dis-
cussed with the nurses. The occurrence of the prescribing changes immedi-
ately following the medical staff presentation strongly suggest its 
I 
impact. Other internal and external influences, such as drug availability, 
pharmaceutical manufacturer promotion, etc. were not, as best determined, 
contributory to these results. Here again, the length of the follow-up 
period was 17 weeks and a ••1asting 11 impact past this time period requires 
re-investigation. It was learned from this situation that the presenta-
tion of a problem dealing with a specific agent (ie. lubricant LAX) 
seems more tangible for the physicians to accept than a general problem 
such as 11 extensive use of LAX . 11 
The head nurse discussion, physician ward rotation and distribution 
of the bran memorandum from the DNS all occurred in t he final two-week 
time period (week 10-17). This close scheduling makes it difficult to 
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determine the impact of each intervention individually. Both the sig-
• 
nificant decrease in saline prescribing (£ < 0.05) and the significant 
increase in bisacodyl orders (£ < 0.01) which occurred during this time 
period, must be considered as the effect of all three interventions 
and the possible latent effects of the previous interventions . The 
20% increase in bisacodyl in this last time period of the post-st~dy, 
however, may primarily be attributed to the impact of t he DNS bran 
memorandum (see Appendix H). The intervention programs conducted by 
the author did not directly promote the increased prescribing of bisa-
codyl . Regardless, the issuance of a statement from the DNS does appear 
to be capable of indirectly influencing prescribing for LAX agents. The 
specific relationships of the head ward nurse discussion and the phy-
sician ward rotation to these prescribing changes is obscure. 
In summary, the interventions proved effective in changing LAX 
prescribing and administration. Rather clear decreases in the routine 
use of bulk-forming agents appeared immediately following the nursing 
staff inservice . Also, routine use of mineral oil preparat ions signifi-
cantly decreased following the medical staff conference. Other pre-
scribing changes noted in the final time period are less ~lear and 
appear to be due to multiple factors. 
If the scheduling of the interventions had been further apart, 
a clearer association between intervention and initial and lasting 
impact could have been made . However, with multifaceted OUR programs 
such as that presented here, this is not always possible or practical. 
CONCLUSION 
The methods of the interventions proved effective in bringing about 
a change in drug utilization in each DUR p~gram. The following changes 
were observed. 
A significant prescribing change toward single daily dosing of PB 
(£ < 0.01) and significant decrease in the prescribing of mineral oil 
preparations(£ < 0.001) following their discussion at the medical staff 
presentations. The approach of this intervention was the presentation 
of DUR data, open discussion of the problem areas and support from two 
physician advocates. 
There was a significant decrease in the prescribing of bulk-forming 
agents (£ < 0.05), following an i~ s ervice education to staff nurses on 
l axative agents, in which the use of dietary bran was emphasized . 
A significant change in chloral hydrate (£ < 0. 05) and flurazepam 
(£ 0.05) admini stration was observed in the post-study period. This 
appeared to be related to the discussion with the head nurses about the 
problems of chronic nightly administration of hypnotics. 
The cost of laxative administration decreased by nearly 50% in the 
post-study period . Thi s primarily refl ects the decrease in bulk-forming 
and lubricant agent prescribing as well as a decrease in l axa tive admin-
i stration. The decrease in administration appeared to be related to 
the routine use of dietary bran. 
In addition to t hese changes in the prescribing and administration 
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of drugs, a unique method of evaluating changes in the frequency of drug 
• prescribing was used in this project . Increased and decreased prescrib-
ing was evaluated according to three physician decisions during a given 
time period; new order, discontinued order and no change order. This 
method allowed for the application of statistical analysis to prescrib-
ing changes in small patient populations. 
Overall, the results of these three OUR programs showed that a 
clinical pharmacist, using these educational methods, can significantly 
improve the quality of drug therapy in the SNF setting . 
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APPENDIX C 
AC DUR HANDOUTa 
0 
LAGUNA HONDA HOSPITAL UTILIZATION REVIEW 
Anticonvulsant Drug Study 
December 1, 1975- February 22, 1976 
PURPOSES OF REVIEW 
1. To investigate the prevalence and patterns of anticonvulsant drug 
usage in chronic care patients at LHH. 
2. To examine and evaluate anticonvulsant drugs as to: 
a) physician prescribing patterns. 
b) nursing efficiency of drug administration. 
c) cost factors of prescribing, administration and 
dispensing of this drug group. 
3. To determine patient outcome of anticonvulsant drug therapy. 
4. To derive and implement practical recommendations for improvement 
of patient anticonvulsant therapy. 
~lETHODS 
l. Patient Selection - All patients on chronic, long-term care wards, 
60 years of age or older were considered as eligible. LHH wards 
excluded from the study included rehabilitation, women section, 
Clarendon Hall, AETC, acute, locked and skilled nursing (M-6 and 
0-6) . A total of 59 patients were found to be receiving anti-
convulsant medications out of 481 eligible patients. From these 
59 patients, 40 (equal numbers of males and females) were randomly 
selected. 
2. Data collection - All data was collected for 12 continuous weeks 
(December 1, 1975- February 22, 1976) from individual patient 
charts by the investigator. 
RESULTS 
1. Table I: Patterns of anticonvul sant usage 
aThese data are not the same as that reported for the pre-study 
period. Dropout patients during the post-study period were excluded 
in the final pre-study data. 
.... . ' :•. 
. . 
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a) prevalence of usage 
b) number of agents prescribed for each patient 
c) distribution of agents per patient 
d) number of patients receiving each agent 
e) dosage range (total daily) 
f) frequency of administration per agent 
Conclusion: 
1. More than half (60.0%) of patients receive one anticonvulsant 
agent {phenytoin) for seizure management. 
2. A small percentage (2.5%) of the patients receive diazepam-as 
a chronic medication for seizure control. 
3. Approximately one-half of the pat ients prescribed phenytoin 
(Dilantin R ) and phenobarbital (PB) received the manufacturer 
prepared combination dosage form. 
4. A trend toward less frequent dosing was demonstrated for pheny-
toin while phenobarbital was predominantly prescribed in divided 
daily doses. 
2. Table II: Nursing efficiency of drug administratiQn 
a) scheduling of dosing intervals 
b) Kardex R transcriptions of physician orders 
c) missed doses 
Conclusion: 
1. Approximately one-half (47 .8%) of the divided da i ly doses are 
schedul ed at irregular time intervals. 
2. Kardex R transcriptions were generally clear and wi thout error, 
however, the administration of phenytoin and PB in the combination 
dosage form may cause possible confusion to nursing staff if not 
clearly designated. 
3. The percentage of missed doses wa s minimal, however, the docu-
mentation of the se mi ssed doses in Nurses• Notes or the 
Treatment and Medication Record was poor (56. 1%) . 
3. Table III: Serum folate determination and folic acid administration 
Conclusion: 
1. A small percentage (5.0%) of the pati ents rece1v1ng chronic 
anti convul sant admini stration are scr eened for possible folic 
acid deficiency. 
2. Approximately 15.0% of the patients were receiving concurrent 
folic acid adminstration. 
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4. Table IV: Outcome 
a) number of reported seizures 
b) cost of anticonvulsant therapy 
Conclusion: 
1. Break-through seizures were minimal (3/12 weeks/40 patients). 
2. Over 50% of the anticonvulsant drug cost expenditure is lost 
in the computerized drug billing procedure. This is attributable 
to the following: 
a) inaccurate coding of drug administrations by 
accounting department personnel. 
b) changes in the pharmacy acquisition drug prices 
without a corresponding up-date of the computer 
Master Code File of drug prices 
Recommendations: 
1. Once a dose i s established, chronic phenobarbital administration for 
seizure control can be given once daily to minimize nursing time, de-
crease the possibility of missed doses and reduce drug costs. 
2. Use of the phenytoin-phenobarbital combination dosage form is not 
recommended based upon: 
a) administration confusion to nursing staff. 
b) slight in crease in drug cost. 
c) less flexible dosage form for selection of 
individualized patient dosage. 
3. Di azepam (Valium®) should be reserved for the treatment of status 
epi l epti cus for which it is the drug-of-choice.l Long -term treatment 
of seizure disorders with diazepam has not been documented or recom-
mended in the med ical li terature.l,2 In additi on, the state Medi-
Ca l Drug Formulary does not reimburse the hospita l when diaz epam is 
used as a chronic medication in epi l epsy . Other alternative agents GD 
such as phenyto in, phenobarbital, primidone or carbamazepine (Tegretol ) 
should be tried in its place. 
4. For pdmidone {r~ysol ine ®) , divided da i~ l y doses should be scheduled 
by the fo ll owing protocol in order to maintain adequate blood l evels 
and decrease the incidence of unwanted side effects. 
b. i.d. 
t. i .d. 
or 
8 8 
8 - 12 - 8 
8 - 4 - 8 
5. Yearly serum folate determinations for all patients on chronic 
References: 1. Medica l Letter 18: 18, Feb. 12, 1976. 
2. Medical Letter 18:25 , March 12, 1976 . 




6. In-service education for accounting department personnel engaged 
with coding of drug administrations in order to generate efficient 
and proper billing of drug adminstrations. 
7. Annual revision of the computer Master Code File of drug prices 
to the current pharmacy acquisition prices. 
Table CI. Patterns of anticonvulsant usage. 
A. Prevalence of usage 
Number of eligible patients 











Distribution of anticonvulsant agents 
Phenytoin (Dilantin ®) alone 
Phenobarbital (PB} alone 
Primidone (Mysol ine ®) alone 
Phenytoin + PB* 
Phenytoin + Primidone 
PB + Primidone 
27 (67.5%) 
11 (27. 5%) 
2 (5.0%) 
per patients 
Phenytoin + PB + Primidone 
Phenytoin + PB + Diazepam (Valium®) 
*manufacturer prepared dosage form 
administered separately 


















4 ( l 0. 0%) 
1 (2 .5%) 
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Table CI. (continued) 
0 
Totals 
E. Dosage range (total daily) 
Phenytoin 100 mgm 1 (2.7%) 
200 mgm 4 (10.8%) 
300 mgm 30 (81.1%} 
400 mgm 2 (5 .4%) 
37 
PB 45 mgm 7 (53.9%) 
60 mgm 2 (15.4%) 
90 mgm 4 (30 .8%) 
13 
Primidone 250 mgm 1 (25.0%) 
500 mgm 2 (50 .0~ ) 
750 mgm 1 (25.0%) 
4 
Diazepam 15 mgm 1 
F. Frequency of Administration 
All agents (n=49) 
Single daily dose 26 {53.1 %) 
Divided daily doses 23 (46.9%) 
Table CII. Nursing Efficiency of Drug Administration 
A. Scheduling of dose intervals 




12 (52 .2%) 
11 ( 47 .8%) 
23 
*Appropriate dose scheduling was considered as: 
b.i.d. 8 8 
t.i.d. 
or 
q. i .d. 
B. Kardex R transcriptions 
Correct 
8 - 12 - 8 
8 - 4 - 8 
8 - 12 - 4 - 8 
48 
Incorrect 1* 
*unclear designation of the use of Phenytoin/PB 
manufacturer prepared dosage form. 
C. Missed doses 
7812. 
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# scheduled doses/ 12 weeks 
# missed doses 41. (0.53%) 
Documenta tion of missed doses (n = 41) 
# documented 
# not documented 
18 (43.9%) 
23 (56.1 %) 
Table CIII. Serum Folate Determination (n=40) 
Within past year 
More than 1 year ago 
Not determination reported in 
patient chart 
# of patients prescribed concurrent 








Table .CIV. Outcome 
A. Number of reported seizures 
B. Cost of anticonvulsant therapy (n=40) 
Admi nistered 








C. Extrapolation to corresponding LHH census 
Mean census** 778 
Anticonvulsant usage 12.3% 




























Table CIV . (continued) 
*Tabulated from the computerized billing value indicated for each drug on the Treatment 
and Medication Record. 
**Tabulated from the monthly census for December 1975, January and February 1976 using acute, 




SH OUR HANDOUTa 
LAGUNA HONDA HOSPITAL UTILIZATION REVIEW 
Sedative-Hypnotic Drug Study 
December 1, 1975- February 22, 1976 
PURPOSES OF REVIEW 
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• 
1. To document the prevalence and patterns of sedative-hypnoticb usage . 
in chronic care patients at LHH. 
2. To examine and evaluate sedative-hypnotic drugs as to: 
a) physician prescribing patterns. 
b) nursing admi nistration of 11 h. s. prn 11 medications. 
c) economic-cost factors of prescribing, administration and 
dispensing. 
3. To determine the cost related outcome of sedative-hypnotic therapy 
at LHH. 
4. To derive and implement practical recommendations for improvement 
of patient sedative-hypnotic drug therapy. 
METHODS 
1. Patient Selection- A total of 100 patients (50 male and 50 female), 
60 years of age or older, were randomly selected from 18 chronic, 
long-term care \'lards. LHH v1ards excluded from the study include 
rehabilitation, womens section, Clarendon Hall, AETC, acute, locked 
and skilled nursing (M-6 and 0-6). At the conclusion of the 12 week 
study, seven patients had dropped out (5 expired and 2 discharged 
to SFGH). 
2. Data Collection - All data was coll ected for 12 continuous weeks 
(December 1, 1975 - February 22, 1976) from ind ividual patient 
charts by the investigator. 
aThese data are not the same as that reported for the pre-study 
period. Dropout patients during the post-study period were excluded 
in the final pre-study data. 
bFor this study, a sedative-hypnotic was defined as an agent prescribed 
only for 11 h.s. 11 administration and \'lhich can induce sleep or cause seda-
tion when given at bedtime. 
RESULTS 
1. Table I: Patterns of sedative-hypnotic usage 
a) prevalence of usage (prescribed) 
b) number of agents prescribed per patient 
c) distribution of agents per patient 
d) number of patients receiving each agent 




A high percentage (81.7%) of patients have a routine order 
for a sedative-hypnotic agent. 
Chloral hydrate is the major sedaiive-hypnotic prescribed 
( 63.2%) wi;kh f1 urazepam ( Da 1 mane® ) and diphenhydramine 
(Benadryl UP) prescribed to a lesser degree, 19.7% and 12.5% 
respectively. 
2. Table II: Patterns of 11 h.s. prn 11 administration 
a) frequency of administration per agent 
b) distribution of agents administered daily 
c) administration of agents prescribed "q.h.s." 
d) specification of "prn" orders · 
e) repeat doses administered 
Conclusion: 
1. Over two-thirds of the sedative-hypnotic orders are adminis-
tered 3 times per week or less with approximately one-half 
(46.3%) not administered at all for _ 12 weeks. 
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2. Approximat ely one-fifth (1 8.8%) of the agents were administered 
eve ry night with chloral hydrate compri sing 73.3% of these 
agents. 
3. T\'tenty percent of the diphenhydramine 11 prn" orders administered 
at bedtime were written without a specified indication. 
4. The incidence of repeat doses administered was very small (0.6%} . 
3. Table III: Cost related outcome of sedative-hypnotic administration. 
Conclusion: 
a) cost of administration for study group 
b) extrapolation to corresponding LHH census 
c) additional loss due to inability to claim monthly 
pharmacy dispens ing fee s for administered benzo-
diazepines. 
1. Over two-thirds of the sedative-hypnotic orders are admin-
istered 3 times per week or less with approximately one-half 
(46.3 
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2. The prescribing and administration of benzodiazepines (flura-
zepam, diazepam and ch lordiazepoxide) for sleep results in an 
overall loss of approximately $2000 .00 per year. 
OBSERVATIONS FOR POSSIBLE RECOM~1ENDATIONS 
I. Problem: benzodiazepine prescribing 
Action: 
l . Decrease prescribing: 
Although flurazepam is currently considered th~ drug-
of-choice for chronic sedative-hypnot i c use, primarily 
due to its lower toxicity and greater safety in potential 
drug overdose, its administration has been shown to be a 
costly expense to LHH. The cost of flurazepam 30mgm 
is 5 times greater than its closest alternative chloral 
hydrate 500mgm (see cost table) and present ly is not 
reimbursed by the ~1edi -Ca l Drug Formulary. 
Therefore, at the present time, f lurazepam prescrib-
ing should be restricted to special situations. 
2. Initiate Medi-Cal Treatment Authorization Request: 
Approval of flurazepam prescribing is justified by 
demonstration that other sedative-hypnotic agent s have 
been tried and failed to be effecti ve, created a 
dependence liability or caused allergic reactions. 
II . Problem: Daily administration of sedat ive-hypnotics. 
Action: 
1. Decrease orders written as "q. h. s. ": 
By placing all sedative-hyrnotic agents on "prn" 
basis will serve to decrease unnecessary dai ly administra-
tion. 
2. Decrease chronic daily administration: 
Chronic , da ily administration of all sedative-
hypnotic agents can be associated with possible tolerance 
and hence a decrease in the effectiveness of the agent 
to induce s leep. 
Cost savings projection: 
Administration of daily sedative-hypnotics comprise 
62 . 2% of the total sedative-hypnotic cost expenditure. 
A decrease in the number of sedative-hypnotics admin-
istered daily by 50% v10uld reflect in an approximate 
30% savings in sedative-hypnotic costs per year. 




Since diphenhydramine is not considered as a 
classic hypnotic agent and can be prescribed for a 
variety of other indications (rashes, allergies, etc.), 
its use as a 11 prn 11 sedative for sleep should be 
specifically stated to eliminate possible confusion 
to nursing staff and reduce its use for unintended 
purposes. 
.... 
Table DI. Patterns of sedative-hypnotic usage. 
A. Prevalence of usage 
Total patient population 
Pateint usage (pres~ribed) 
B. Number of agents prescribed per patient 
1 
2 
C. Distribution of agents per patient (n=76) 
chloral hydrate 
fl urazepam (Da lmane ®) 
diphenhydramine (Benedryl ® ) 
thioridazine (Mellaril ®) 
diazepam (Valium®) · 
chloridazepoxide (Librium ®) 
fluphenazine (Prol ixin ®) 
chloral hydrate + thioridazine 
chloral hydrate + chlorpromazine (Thorazine®) 
chloral hydrate + diphenhydramine 
D. Number of patients receiving each agent (n=76) 
chl ora 1 hydrate 











76 {81. 7%) 
72 (94.7%) 
4 ( 5. 3%) 
44 (57. 9%) 
15 (19.7%) 
9 ( 11. 8%) 
1 (1.3%) 
1 (1 .3%) 
1 (1.3%) 
1 (1.3%) 
2 (2 .6%) 
1 (1.3%) 











Table DI. (continued) 
TOTAL 
E. Prescribed dosage per agent 
chloral hydrate 500 mgm 48 ( 100 .0%) 
f1urazepam 15 mgm 9 (60 .0%) 
30 mgm 6 (40~0% ) 
diphenhydramine 50 mgm 10 (100.0%) 
thioridazine 25 mgm 1 (33. 3%) 
50 mgm 2 (66.6%) 
diazepam 5 mgm 1 
chlordiazepoxide 10 mgm .1 
chlorpromazine 25 mgm 1 
Table Oil. Patterns of "h.s . prn" administration. 











*Administered primarily 4 times or more per week for 12 weeks. 
**Administered primarily 3 times or less per week for 12 weeks . 
B. Distribution of agents administered daily (n=l5) 
Chloral hydrate 11 (73.3%) 
Flurazepam 2 (13. 3%) 
Diphenhydramine 1 (6.6%) 
Chlorpromazine 1 (6.6%) 
C. Administration of sedative-hypnotic agents prescribed "q.h.s. 11 (n=5) 
Daily 4 (80.0%) 
More regular 0 
Less regular 
Not administered 
D. Specification of 11 prn" orders regarding: 
diphenhydramine (n=lO) 
specified 
not spec ified 
prescribed "q.h.s." 
diazepam (n=l) and chlordiazepoxide (n=l) 
both single orders were not specified 
E. Repeat doses admini stered 
Total # of doses admini stered/12 weeks 
# of repeat doses/12 weeks 
1 (20.0%) 
0 
7 (70. 0%) 
2 (20. 0%) 





Table DIII. Cost related outcome of sedative-hypnotic administration. 




B. Extrapolation to corresponding LHH census 
Mean censusb = 778 patients 











Cost/pt. day $value/year 
(¢) (365 days) 
Administered 





C. Additional loss due to inability to claim monthly pharmacy dispensing 
administered benzodiazepinesd. 
fees for 
Medi-Cal monthly dispensing fee = $2 .72 
# of unclaimed $ Amount/ # of patient $ Amount/ 
fees/3 months 3 months months (n=93) patient month 










Table DIII (continued) 
aTabulated from the computerized billing value indicated for each drug on the Treatment 
and Medication Record for those agents reimbursed by the Medi-Cal Drug Formulary. 
bcalculated from the monthly census for December 1975, January and February 1976, using 
acute, sub-acute and minimal LHH ward categories. 
closs for cost of drug only. 
dBenzodiazepines (flurazepam, diazepam and chlordiazepoxide) are presently not covered by 
the Medi-Cal Drug Formulary for sedative-hypnotic use. 






TABLE OF SOME SEDATIVE-HYPNOTIC COSTS 
AGENT 
Benzodiazepines: 
fl urazepam (Da lmane ® ) 
diazepam (Valium®) 
chlordiazepoxide (Librium ®) 
Mi see 11 aneous: 













SEDATIVE-HYPNOTIC AGENTS LISTED IN THE MEDI-CAL DRUG FORMULARY* 
*May l, 1974. 
amobarbital (Amytal ®) 
amobarbital sodium (A®tal Sodium®) 
aprobarbital (Alurate ) 
butabarbi ta 1 (But i so 1 ® , Butacaps ® ) 
carbromal and pentobarbital . sodium (Carbrital ®) 
chloral hydrate 
ethchlorvynol (Placid£ ®) 
glutethimide (Doriden ) 
hexobarbital 
methaqua 1 one (Parest ® , Quaal ude ® , Somnifac ® , Sopor® ) 
methyprylon (Noludar ®) 
pentobarbital (Nembutal ® ) 
secobarbital (Seconal®) 







LAX OUR HANDOUTa 
LAGUNA HONDA .HOSPITAL UTILIZATION .REVIEW 
Laxative Drug Study 
December 1, 1975- February 22, 1976 
PURPOSES OF .REVIEW 
1. To document the prevalence and patterns of laxative usage in chronic 
tare patients at LHH. 
2. To examine and evaluate laxative agents as to: 
a) physician prescribing patterns. 
b) nursing administration of "prn" medications. 
c) economic-cost factors of prescribing, administration and 
dispensing. 
3. To determine the cost related outcome of laxative therapy at LHH. 
4. To derive and implement practical recommendations for improvement 
of patient laxative therapy. 
METHODS 
1. Patient Selection- A total of 100 patients (50 male and 50 female), 
60 years of age or older, were randomly selected from 18 chronic, 
long-term care wards. LHH wards excluded from the study include 
rehabilitation, womens section, Clarendon Hall, AETC, acute, locked 
and skilled nursing (M-6 and 0-6) . At the conclusion of the 12 week 
study, seven patients had dropped out (5 expired and 2 discharged 
to SFGH). 
2. Data Collection - All data was collected for 12 continuous weeks 
(December 1, 1975- February 22, 1976) from individual patients 
charts by the investigator. 
RESULTS 
1. Table I: Patterns of laxative usage 
a) prevalence of patient usage (prescribed) 
aThese data are not the same as that reported for the pre-study 
period. Dropout patients during the post-study period were excluded 
in the final pre-study data. 
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b) number of laxatives per patient 
c) distribution of laxatives prescribed 






Virtually all patients (93 .6%) have at least one laxative in 
their drug regimen. 
The number of laxa tives prescribed per patient ranged from 
1 - 4 with a mean of 2.05. 
A total of 16 different laxative products were prescribed com-
prising 6 pharmacological categories. 
The three ~st frequently prescribed laxatives were bisacodyl 
(Dulocolax~ )~uppositories (50.6%), milk of magnesia (49.4%) 
and Metamucil ~ (25.3%). 
2. Table II: Patterns of 11 prn 11 prescribing and administration 
a) frequency of administration per laxa tive category 
b) laxative orders per agent 
c) number of patients with laxative-of-choice orders 
d) number of laxatives per laxative-of-choice order. 
Conclusion: 
1. In general, bisacodyl suppositories were administered 3 times . 
or less each week for the 12 weeks. The same was found for 
milk of magnesia (M .O.M.), however, over one-half (53 . 5%) 
of the M.O.M. orders were not administered. 
2. A low percentage (13.4%) of the stimulant laxatives (excluding 
bisacodyl) were administered 4 or more times per week for 
12 weeks. 
3. Bu lk-forming laxatives and stool softeners, which need to be 
administered regu larly in order to exert their action, were 
predominantly administered 4 or more times each week. Only 
4.0% of the bulk-forming and 4.5% of the stool softeners were 
administered on a less regular basis. 
4. A total of 45.4% of the mineral oil preparations were admin-
i stered 4 or more times per week for 12 weeks with daily 
administration accounting for 22.7%. 
5. Approximately 20.0% of patients have a laxative-of -choice 
order. 
3. Table III: Cost related outcome of la xative administration 
a) cost of administration for study group 
b) extrapolation to corresponding LHH census. 
Conclusion: 
1. Laxative administration results in approximately an 
$11,000.00 per year expense to LHH. 
OBSERVATIONS 
1. Virtually all patients have orders for a laxative. The addition 
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of 8 - 12 grams of fiber (usually bran), to the daily diet would 
serve as a preventative approach toward patient constipation and 
possibly reflect a decrease in the usage and dependency of laxa~i ves . 
2. If a laxative is needed for chronic administrations the bulk-forming 
agents are considered the best choice because they are not absorbed 
in the digestive tract and exert a 11 natura l 11 effect of increasing 
the frequency of bowel movements and softening the stools. 1 
3. Numerous laxatives are being prescribed in the bulk-forming, stimu-
lant, lubricant and stool softening categories. If the prescribing 
was limited to 1 - 2 agents per l axative category, a possible 
savings could occur by selecting the agents with the best acquisi-
tion prices. 
4. The intermitant use of bisacodyl should be continued only when it 
is needed. 
5. Bulk-forming laxatives and stool softeners should be administered 
daily as is frequent ly done. 
6. t~ineral oil preparations (including Kondremul ® and Agoral ®) 
shou ld be reserved for occasional use only because its chronic use 
can potentially result in: 
1) impaired absorption of oil soluble vitamins leading 
to impairment of calcium and phosphorus metabolism 
and lowered prothrombin levels, 
2) lipoid pneumonia, 
3) enhanced absorption of the mineral oil by co-
administration with stoo l softeners .2 
7. The laxative-of-choice order can potentially be costly from the 
standpoint that the nurs ing staff may not be aware of the most 
effective, safest and least expensive laxative options. 
1Federal Register Part II, March 21, 1975. 
2Ibid. 
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Table EI. Patterns of Laxative Usage. 
TOTAL 
A. Prevalence of usage 
Total patient population 93 
Patient usage (prescribed) 87 (93.6%) 
B. Number of laxatives per patient 
1 26 (29.9%) 
2 38 (43.7%) 
3 17 (19. 8%) 
4 6 (6.9%) 
Average = 2.05 
c. Distribution of laxatives prescribed (n=87) 
Bulk-forming 
Metamuci 1 ® 22 (25 .3%) 
Konsyl ® 2 (2.3%) 
Effersyll ium ® · 1 (1. 2%) 
Stimulant 
Oulcolax ® p.r. 44 (50.6%) 
p.o. 2 (2.3%) 
Cascara 12 ( 18 .8%) 
Ex-lax® 2 (2.3%) 
Senokot ® 1 (1. 2%) 
Saline 
Milk of Magnesia 43 (49.4%) 
Hyperosmotic 
Glycerine p.r. 4 (4.6%) 
Lubricant 
Agoral ® 11 (12.6%) 
Kondremul ® 9 (10.3%) 
Mi nera 1 Oi 1 2 (2.3%) 















1 0 { 11.5%) 
6 {6.9%) 
2 (2 .3%) 
4 (4.6%) 
category (n:.:l77) 
25 (14 .1%) 
61 (34.5%) 
43 (24.3%) 





Table EII. Patterns of 11 prn 11 prescribing and administration (percent). 





Dulcolax ) Dulcolax R Saline Lubricant 
Daily 60.0 6.7 
More Regulara 16.0 6.7 
Less Regular b 4.0 60.0 
Not Adminis-
tered 20.0 26.7 
(r.=25) (n=15) 
B. Laxative orders per agent (n=177) 
Specific 
Laxative-of-choice (LOC) 
No order written 













25 (14.1 %) 
11 ( 6. 2%) 
















Table Eli. (continued) 





aAdministered primarily 4 times or more per week for 12 weeks. 









Table EIII. Cost realted outcome of laxative administration.a 
A. Cost of administration for study group 
# of pt. days/ 
Cost ( $) 12 weeks 
300.49 7812 
B. Extrapolation to corresponding LHH census 
Mean censusb = 778 patients 
Cost/pt . day 
($) 







aAt the present time, the Medi-Cal Drug Formulary does not reimburse for the administration of 
laxati ves. Laxative costs are totally financed by LHH. 
bCalculated from the monthly census for December 1975, January and February 1976 using acute, 
sub-acute and mini mal LHH ward categories. 
cAmount extrapolated to mean LHH census (n=778). 
N -~ 





Effersyll i urn® 
Stimulant 
















Agoral ® plain 
Stoof Sofeners 
DSS generic (Colace, Softeze) 
Surfac ® 






















HEAD NURSE DISCUSSION - TOPIC OUTLINE 
I. Introduction 
A. ~1ethods 
B. Medical Staff Conference 
C. Communication of Information - head nurse ~esponsibility 
II. Anticonvulsant OUR 
A. Nursing Efficiency of Drug Administration 
1. Kardex Transcriptions 
2. Missed doses 
3. Scheduling of dose intervals· 
III. Sedative-Hypnotic OUR 
A. Specification of PRN orders 
B. Repeat doses Administered 
C. Choice of Agent - benzodiazepine prescribing 
D. Daily Admini stration of Hypnotics 
IV. LAX OUR 
A. Excessi ve Use of LAX Agents - Use of bran 
B. Excessive LAX Costs - LAX cost table 
C. 11 IDEAL 11 LAX Administration 



















Konoremul ® plain 
Agoral ® plain 
Stool softeners 
DSS generic (Colace, Softeze ) 
Surfac® 


















23 . 0/5cc 
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APPENDIX G 
· LAX STAFF NURSE IN-SERVICE - LECTURE OUTLINE 
A. Gastro-Intestinal Physiology 
B. Criteria- 11 Idea1 11 Laxative 
C. LAX Category Discussion (Stimulant, Saline, Osmotic, Lubricant, 
Stool-softening, bulk-forming) 
1. Agents 
2. Mode of Action 
3. Adverse Effects 
a. Acute 
b. Chronic 
4. Drug Interactions 
5. Recommended Administration 
D. High-Fiber Diet 
1. Mode of Action 
2. Bran Use 
E. Drugs Which Can Cause Constipation 
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APPENDIX H 
DNS Mn10RANDUM - USE OF BRAN 
July 8, 1976 
MEMORANDUM 
TO : ADN 1 S, Nursing Supervisors, Head N~rses 
FROM: V. Leishman, R. N., Director of Nursing 
I encourage all Head Nurses to substitute bran for cathartics. 
Those wards using bran are finding it successful and less 
expensive. Since it is a natural food an M. D.•s order is not 
required . 
Start with two tablespoons on the patient•s cereal, then increase 
or decrease per need of individual patients . Adequate fluids is 
important. 
If patient has not had a bowel movement in four days have a P.R.N. 
order for a suppository. 
Bran is available in the Diet Kitchen. 
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In one month I would like a brief report regarding the success of this 
project . 
Any questions - please discuss with area supervisor. 
220 
APPENDIX I 
HEAD ~lARD NURSE SURVEY - USE OF DIETARY BRAN 
QUESTION: RESPONSE: 
Was your ward ever administered Yes: 16/17 (94%) ( 
bran to the patients? No: 1/17 {6%) 
If bran has been admin istered, a) Other nurses 5/16 (31%) 
where did you first hear of its b) DNS memo 5/16 (31%) 
use? c ) LAX OUR pre-
sentation 3/16 (19%) 
d) Ward Physician 2/16 ( 13%) 
e) Not Known l/1 6 (6%) 
What was the approximate date a) before LAX in-
started? service 3/16 ( 19% ) 
b) after LAX in-
service 12/16 (75%) 
c ) Not known l / 16 (6%) 
Is bran sti ll being admi ni stered? a) Yes 13/16 (82%) 
b) No 2/16 ( 13%) 
c) Not known 1/16 (6%) 
How much bran was admin istered? 1 oz 13/16 (82%) 
>l oz 3/16 ( 19%) 
Approximately how many pat i ents a) nea rly all 9/16 (56% ) 
are using bran? b) approximately all 3/16 (1 9%) 
c) a few 2/16 (1 3% ) 
d) not known 2/16 (13%) 
APPENDIX J 









A patient complains to you of no bowel movement for 
a couple of days and some mild abdominal discomfort. 
The possibility of a fecal impaction is checked and 
ruled out. You decide to start the patient on laxa-
tive therapy. Considering safety, efficacy and re-
sults, what would be your choice of agent(s). 
What are some possible side effects of frequent admin-
istration (> 4x/week) of bisacodyl (Dulcolax ®) sup-
positories .-
What is the difference between the mode of action of 
dioctyl sodium sulfo~uccinate (DSS, Colace®, Softeze®, 
etc.) and Metamucil ~. · . 
Can you name some m~dications which might be suspected of 
causing constipation? 




Based upon safety and minimal chance for side effects, 
what laxative group or agent would you consider best 
suited for chronic, daily administration. 
What are some possible side effects of frequentY,®adminis-
tration (> 4 times/week) of bisacodyl (Dulcolax ) sup-
pas itori es. 
What is the difference between the mode of action of 
dioctyl sodium sulfo3uccinate (DSS, Colace, Softeze, etc.) 
and ~1etamuc i 1 . 
II. 
I I I. 
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4. Can you name some medications which mi ght be suspected of 
causing constipation? 
Scoring per question 
A. Two points = correct answer 
B. One point = partially correct 
c. Zero point = incorrect answer 
D. Total points per exam = 8 points 
Examination Scores for each Nursing Shift. 
A. Morning Shift Nurses 
1. Pre Test Examination 
a. Number = 45 
b. Mean= 3. 58 points 
c. Standard deviation = + 1.47 
2. Post-Test Examination 
a. Number = 45 
b. Mean = 6.60 
c. Standard deviation = + 1.32 
3. Statistical comparison (Student .!_-test) 
a. degrees of freedom = 88.0 
b. t-value = 10.26 
c. £_-value = <0 .001 
B. Afternocn Shift Nurses 
1. Pre-Test Examination 
a. Number = 39 
b. Mean = 3.15 
c. Standard deviation - 1 .42 
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2. Post -Test Exami nation 
a. Number = 39 
b. Mean = 6.69 
c. Standard deviati on = 1.06 
3. Statist ical Comparison (Student !-test) 
a . degrees of freedom = 76 .0 
b. t -val ue = 12.47 
c. £_-val ue = <0. 001 
c. Night Shift Nurses 
1. Pre-Test Exami nat ion 
a . Number = 40. 0 
b. Mean = 3.43 
c. Standard deviation - 1. 36 
2. Post-Test Examination 
a. Number = 40.0 
b. Mean = 6.48 
c. Standard deviation 1.80 
3. Statisti cal comparison (Student !-test) 
a. degrees of freedom = 78. 0 
b. t-val ue = 8.57 
c. £_-val ue = <0.001 
